



## OPEN ACCESS

EDITED BY  
Ashley S. Harms,  
University of Alabama at Birmingham,  
United States

REVIEWED BY  
Francesca Massenzio,  
Università di Bologna,  
Italy  
Mirko H. H. Schmidt,  
Dresden University of Technology, Germany

\*CORRESPONDENCE  
Kai Yao  
✉ kyao21@outlook.com

<sup>†</sup>These authors have contributed equally to this work

SPECIALTY SECTION  
This article was submitted to  
Molecular Signalling and Pathways,  
a section of the journal  
Frontiers in Molecular Neuroscience

RECEIVED 16 November 2022  
ACCEPTED 03 January 2023  
PUBLISHED 23 January 2023

CITATION  
Fu X, Feng S, Qin H, Yan L, Zheng C and  
Yao K (2023) Microglia: The breakthrough to  
treat neovascularization and repair blood-  
retinal barrier in retinopathy.  
*Front. Mol. Neurosci.* 16:1100254.  
doi: 10.3389/fnmol.2023.1100254

COPYRIGHT  
© 2023 Fu, Feng, Qin, Yan, Zheng and Yao. This  
is an open-access article distributed under the  
terms of the [Creative Commons Attribution  
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or  
reproduction in other forums is permitted,  
provided the original author(s) and the  
copyright owner(s) are credited and that the  
original publication in this journal is cited, in  
accordance with accepted academic practice.  
No use, distribution or reproduction is  
permitted which does not comply with these  
terms.

# Microglia: The breakthrough to treat neovascularization and repair blood-retinal barrier in retinopathy

Xuefei Fu<sup>1†</sup>, Shuyu Feng<sup>1†</sup>, Huan Qin<sup>1</sup>, Lin Yan<sup>1</sup>, Caiyan Zheng<sup>1</sup> and Kai Yao<sup>1,2,3\*</sup>

<sup>1</sup>Institute of Visual Neuroscience and Stem Cell Engineering, Wuhan University of Science and Technology, Wuhan, China, <sup>2</sup>College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, China, <sup>3</sup>Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan, China

Microglia are the primary resident retinal macrophages that monitor neuronal activity in real-time and facilitate angiogenesis during retinal development. In certain retinal diseases, the activated microglia promote retinal angiogenesis in hypoxia stress through neurovascular coupling and guide neovascularization to avascular areas (e.g., the outer nuclear layer and macula lutea). Furthermore, continuously activated microglia secrete inflammatory factors and expedite the loss of the blood-retinal barrier which causes irreversible damage to the secondary death of neurons. In this review, we support microglia can be a potential cellular therapeutic target in retinopathy. We briefly describe the relevance of microglia to the retinal vasculature and blood-retinal barrier. Then we discuss the signaling pathway related to how microglia move to their destinations and regulate vascular regeneration. We summarize the properties of microglia in different retinal disease models and propose that reducing the number of pro-inflammatory microglial death and conversing microglial phenotypes from pro-inflammatory to anti-inflammatory are feasible for treating retinal neovascularization and the damaged blood-retinal barrier (BRB). Finally, we suppose that the unique properties of microglia may aid in the vascularization of retinal organoids.

## KEYWORDS

microglia, retinopathy, retinal neovascularization, blood-retinal barrier, retinal inflammation

## 1. Introduction

Microglia, which are derived from the yolk sac, are the primary resident mononuclear macrophages in the retina and are regarded as the first line of active immune defenders. They express many pattern recognition receptors and immune receptors, such as *AT1R*, *AT2R*, and *TβRII*, empowering their function of guiding blood vessel formation, guaranteeing the survival of neurons, monitoring neuronal activity, pruning synapses of neurons, sustaining density of dendritic spines and clearing apoptotic cells or protein aggregates (Takahashi et al., 2005; Parkhurst et al., 2013; Cramer et al., 2022; He et al., 2022; Figure 1). Retinal microglia mainly present high branch structures to guarantee retinal homeostasis. When the balance of the retinal microenvironment is broken, microglia change their phenotypes, such as amoeboid mode, and stay in an activated state. Activated microglia are one of the essential neurotoxic mediators of neuroinflammation (Deng et al., 2009; Zhao et al., 2015). They rapidly move to damage sites and secrete pro-inflammatory factors (e.g., *IL-1β*, *IL-6*, *TNF-α*), chemokines (e.g., *CCL2*, *CCL4*, *CXCL10*) resulting in secondary damage to neuronal death, thereby accelerating the disease progression of patients (Wu et al., 2021; Puthenparampil et al., 2022).

The retina, a highly active tissue member of the central nervous system, requires high oxygen consumption and metabolic demands. The retinal vascular systems transport nutrients to the retina and break down metabolites. In retinal diseases, such as proliferative diabetic retinopathy and retinopathy of prematurity, neovascularization exacerbate the loss of sight. Microglia participate in neovascularization and present co-localization with the neovascular plexus. According to recently published papers, researchers classified microglia into pro-inflammatory and anti-inflammatory based on the classification method of macrophages (Cano-Cano et al., 2021). The conversion from the pro-inflammatory microglia to the anti-inflammatory-microglia effectively reduces the formation of neovascularization (Zhou et al., 2021). In addition, endothelial cells cooperate with other types of cells and form the blood-retinal barrier (BRB) which strictly limits the exchange of various molecules and segregates the plasma and the tissue. Activated microglia promote the dysfunction of BRB which further aggravates plasma leakage and the death of cells. And it is possible that interventions targeting microglia could alleviate neovascularization and the damage to the blood-retinal barrier, thereby helping patients preserve their sight.

This review narrates the correlation of microglia with retinal neovascularization and the blood-retinal barrier. Targeting microglial activation may represent an attractive therapeutic method in retinopathy. Microglia involve in retinal vascularization during normal retinal development. Under some retinopathy, microglia participate in pathological angiogenesis, particularly in hypoxia conditions. The large number of inflammatory factors released by continuously activated microglia can accelerate the loss of vision and lead to the death of retinal endothelial cells, pericytes, retinal pigment epithelium (RPE), and neurons. Pro-inflammatory microglial death is fatal to the retinal disease process. Hence, we recapitulate three microglial signaling pathways we are more interested in. They may monitor retinal vascular function

Abbreviations: 6-OHDA, 6-Hydroxydopamine; ACE2, Angiotensin converting enzyme 2; AMD, Age-related macular degeneration; AT1R, Angiotensin II type 1 receptor; AVE, Masr agonist, Ave0991; CCL5, C-C motif chemokine ligand 5; CNS, Central nervous system; CSC, Central serous chorioretinopathy; CSF-1R, Macrophage colony stimulating factor-1 receptor; CX3CR1, C-X3-C motif chemokine receptor 1; DAT, Dopamine transporters; DIZE, Diminazene aceturate Ace2 activator; DR, Diabetic retinopathy; EAU, Experimental autoimmune uveitis; ENTPD, Ectonucleoside triphosphate diphosphohydrolase; GCL, Ganglion cell layer; GSDMD, Pore-forming protein gasdermind; HIF-1A, Hypoxia-inducible factor; IBA1, Ionized calcium binding adaptor protein 1; IFN- $\gamma$ , Interferon gamma; IGF1, Insulin like growth factor 1; IL-1 $\beta$ , Interleukin-1 $\beta$ ; INL, Inner nuclear layer; IOP, Intraocular pressure; IPL, Inner plexiform layer; IR, Ischemia-reperfusion injury; iBRB, Inner blood-retinal barrier; MAPK, Mitogen-activated protein kinase; MR, Mineralocorticoid receptor; NF- $\kappa$ B, Nuclear factor-kappa B; NMDA, N-methyl-D-aspartate; NOX, Nicotinamide adenine dinucleotide phosphate oxidase; NRF2, Nfe2-like bzip transcription factor 2; NV, Neovascularization; OIR, Oxygen-induced retinopathy; ONL, Outer nuclear layer; OPL, Outer plexiform layer; oBRB, Outer blood-retinal barrier; PD, Parkinson's disease; PKC, Protein kinase C; PKD, Polycystic kidney disease; PP2A, Protein phosphatase 2a; RAP, Retinal angiomatous proliferation; BRB, Blood-retinal barrier; RD10, Retinitis pigmentosa; RMEC, Retinal microvascular endothelial cells; ROCK, RhoA/rhokinase; ROS, Reactive oxygen species; RPE, Retinal pigment epithelium; STAT3, Signal transducer and activator of transcription proteins 3; STZ, Streptozotocin; Tgfb, Transforming growth factor beta; TH, Tyrosine hydroxylase; TNF- $\alpha$ , Tumor necrosis factor- $\alpha$ ; TPSO, Translocator protein; VEGF, Vascular endothelial growth factor; ZO-1, Zonula occluden-1.

and decipher how microglia migrate near blood vessels through intercellular signaling crosstalk. This evidence demonstrates the vital role of microglia in the retinal vasculature and BRB. Finally, we summarize the research progress of microglia induced by iPSC (iMG) which is a reliable method to predict the molecular mechanisms of retinal microglia *in vitro*. And the unique properties of microglia may contribute to vascularizing human retinal organoids.

## 2. Retina microglia, retina vessel, and blood-retinal barrier

### 2.1. Microglia in retina

#### 2.1.1. Derivation and localization of retinal microglia

Yolk sac progenitor cells in gastrula ultimately evolve into retinal microglia through three developmental waves from differentiation to primitive bone marrow cells. At mouse E7.0–7.5, the yolk sac progenitor cells in the blood land specifically express the RUNX family transcription factor 1 (*Runx1*) and differentiate to C-kit<sup>+</sup> early bone marrow erythroid progenitor cells. At mouse E8.0, bone marrow erythroid progenitor cells enter the first wave of growth and precisely express *CD41* and *CD45*. At E8.25, *CD41*<sup>+</sup> and *CD45*<sup>+</sup> cells access the second wave of development and further distinguish to the precursor microglia under the regulation of transcription factors such as SPi-1 proto-oncogene (*PU.1*), interferon regulatory factor (*Irf8*) and *Runx1*. At mouse E9.5, the precursor microglia enter the central nervous system (CNS) supported by Sodium/Calcium exchanger protein (*NCX-1*) and then colonize in the retina (Ginhoux et al., 2010; Prinz et al., 2021). At mouse E10.5, these cells eventually differentiate into the naive microglia under the stimulus factor of transforming growth factor beta (*Tgfb*), colony stimulating factor 1 receptor (*CSF1R*), and interleukin 34 (*IL34*). EMR1/ADGRE1 (*F4/80*<sup>+</sup>) microglial population can be identified in the retina at E11.5 (Ajami et al., 2007; Tay et al., 2017). At mouse E12.5, the number of *F4/80*<sup>+</sup> cell populations steadily increases and then proliferates and migrates from the central area to the retinal periphery (Santos et al., 2008). At mouse E14.5, microglia possess the function of synaptic pruning and shaping neural circuits (Figure 1A).

#### 2.1.2. Microglial colonization and recolonization after ablation

Microglia progressively migrate to the whole retina during development and are finally located in ganglion cell layer (GCL), inner plexiform layer (IPL), outer plexiform layer (OPL), and nerve fiber layer (NFL) layers (Lee et al., 2008). Microglial *CSF1R* is one of the basic receptors to colonize the retina (Ginhoux et al., 2010). *CSF1R*, as a tyrosine kinase transmembrane receptor, has two activating ligands (Wei et al., 2010); (1) *CSF-1*, known as macrophage colony stimulating factor (M-CSF), plays an essential role in regulating the proliferation, differentiation, and survival of macrophages (Sherr et al., 1985); (2) *IL34*, mainly produced by glial cells and neurons, considers a substitute ligand for *CSF-1* (Wei et al., 2010). When *CSF-1* and *IL34* bind to *CSF1R*, they encourage non-covalent dimerization of the receptor chains and transphosphorylation of tyrosine residues (Yu et al., 2008). And *CSF-1* and *IL34* have different affinities for D2 and D3 protein domains from *CSF1R* (Stanley and Chitu, 2014). Furthermore, unlikely microglia in OPL, microglia depend on *IL-34* secreted by other neurons




FIGURE 1

(A) A stepwise microglia developmental program in the retina. Mature microglia maintain a stable population derived from self-renewal. E-embryo. (B) Ramified microglia can be activated to two polarized phenotypes: M1 and M2. The polarization of M1 microglia increased the expression level of proinflammatory factors. Moreover, the polarization of M2 microglia expressed a high level of anti-inflammatory factors. (C) The functions of microglia in healthy retina tissue: Phagocytosis of apoptotic cells and debris; releasing neurotrophic factors to neurons; maintaining neural circuits; ensuring the survival of neurons; pruning neuronal synapses; promoting angiogenesis in retinal development; controlling the retinal vascular blood flow rate.

to localize in IPL and have the feature of assisting cone and rod in transferring chemical signals (Greter et al., 2012).

The neuronal regeneration capacity is limited in the damaged adult mammalian retina (Jorstad et al., 2017). Nevertheless, microglia repopulate the retina *via* individual mitosis or migration of the microglia/macrophage outside the retina to guarantee population quantity (Zhang et al., 2018). Huang et al. used PLX5622 to eliminate nearly all endogenous microglia in the retina of *Cx3cr1<sup>+/GFP</sup>* transgenic mice and discovered two microglial refilling ways: The epiotic microglia of the optic nerve enter the retinal optic disc and then refill from the retinal center to retinal periphery; another microglial refill way derived from corpus ciliare/iris is in the opposite direction with above (Huang et al., 2018a). In addition, the newly recolonized microglia compulsively own similar phenotypes to the endogenous microglia in function, morphology and proliferation under the influence of the retina-tissue environment (Jin et al., 2017; McPherson et al., 2019).

### 2.1.3. The classification of retinal microglia

Retinal neuronal activity can affect microglial phenotypes (Anderson et al., 2022). The polarization phenotypes of retinal microglia present two extreme states: pro-inflammatory (M1) and anti-inflammatory (M2; Figure 1B). M1-microglia stay in “Classical activation” which secretes high levels of *TNF-α*, *IL-1β*, *ROS*, etc. Retinal *IL-1β* is primarily expressed by microglia and adding small doses of

exogenous *IL-1β* increases neuronal survival ability in the excitotoxic condition (Todd et al., 2019). Appropriate activation of M1 microglia also facilitates axonal regeneration in trauma sites (Kigerl et al., 2009). However, continued activation of M1 microglia leads to irreversible neuronal damage (Tang and Le, 2016). In RD10, activated infiltrating microglia continuously secreted *IL-1β* which further accelerated the degeneration of the rod (Zhao et al., 2015).

The microglial phenotypes are in dynamic alternation during the disease process. M2 microglia can be subdivided into “alternative activation” and “acquired deactivation,” hinging on the activation environment and stimulation factors (Walker and Lue, 2015; Siddiqui et al., 2016). Alternative activated M2 microglia are heavily linked with functions such as anti-inflammatory repair and extracellular matrix reconstitution. In contrast, acquired deactivated M2 microglia convert their phenotype in response to anti-inflammatory factors (e.g., *TGFβ1*, *IL-4*) from the environment (Caruso et al., 2020; Chen et al., 2022). M2 microglia increase phagocytosis of erythrocytes and tissue debris, which facilitates hematoma regression (Lan et al., 2017). M1 transformation to M2 microglia alleviates the degeneration of photoreceptors in the mouse model RD1 (Zhou et al., 2018; Figure 1B). The conversion of the M1/M2 phenotype in the appropriate period of acute or chronic retinopathy may provide better therapeutic benefits.

However, with the discovery of the biomarker, retinal microglia likewise generated different subsets of species, and their classification

should not be limited to M1 or M2 in the fully polarized state (Wieghofer et al., 2021). In the meanwhile, Liu et al., had pointed out that a proliferative retinopathy-associated subset of microglia presented to perivascular newborn tufts in the oxygen-induced model (Liu Z. et al., 2022). Therefore, a rational classification of these microglia subsets and naming them with specialized nomenclature is necessary.

## 2.2. Microglia correlation with retinal vasculature and BRB in retina

Microglial branches contact retinal blood vessels, secrete nutritional factors and angiogenic factors, control the apoptosis of pericytes and endothelial cells, and timely eliminate redundancy vessel debris which play an outstanding significance to maintaining retinal function (Ritter et al., 2006; Jolivel et al., 2015; Harsing et al., 2021). They regulate vessel diameter and blood flow velocity through neurovascular coupling (Császár et al., 2021; Mills et al., 2021). Astrocyte and Müller cells are also members of neurovascular coupling. Astrocytes mainly contact the superficial vascular plexus and the regulation ability of Müller cells is principally limited in the intermediate vascular plexus in stable conditions (Biesecker et al., 2016).

IPL and OPL are the main oxygen-consuming layers (Yu and Cringle, 2001). In these layers, microglial branches co-locate with blood vessels which is sufficient to justify the importance of microglia to the retinal blood vessel and the BRB. Therefore, in this section, we briefly introduce the structure of retina and then summarize the relevance of microglia to the retinal neovascularization and BRB.

### 2.2.1. Structure of retina

Retina, as a functional unit of the CNS, is mainly composed of six types of neurons (rod, cone, amacrine, bipolar, horizontal and ganglion) which convert light from the external environment into neural chemical signal and then transfer it to the brain through the optic nerve. And there are three species of glia cells; thereinto, astrocyte and Müller provide retina nutrition and supporting function. Microglia, as the third type of glia in the retina, supervises the homeostasis of the retinal environment in real time and resists foreign microorganism invasion. In structure, the retina is divided into: (1) ONL: cytons of cone and rod; (2) OPL: synapses of cones, rods and horizontal; (3) INL: cytons of bipolar, horizontal and amacrine and Müller; (4) IPL: synapses of bipolar, amacrine cells, retinal ganglion cells and Müller; (5) GCL: cytons of retinal ganglion cells (Figure 2).

### 2.2.2. Retinal vasculature

The retina of humans, mice and rats have formed three kinds of vasculature systems in the long course of evolution. And the sequence of their development is choroidal vasculature - hyaloid vasculature-retinal vasculature (Lutty and McLeod, 2018). Retina, as a high oxygen consumption and metabolic demand tissue in the CNS (Kooragayala et al., 2015), has a dual blood supply vascular system: (1) Retinal vasculature: Central artery and vein radially extend along retinal exterior and then form arterioles and venules. Arterioles expand to the IPL and OPL layers and then continue to nurture capillaries. Blood backflow to venules along the capillaries eventually returns to the central vein and leaves the visual system through the optic nerve, and completes the blood cycle of vision. At 14 weeks of gestation in humans, the retinal vasculature starts to develop and enters the epilogue at 23 weeks (Hasegawa et al., 2008). Unlike humans, the

retinal vasculature of the mouse comes to maturity about 1–2 weeks after postnatal development, and the time of maturation varies between strains (Stahl et al., 2010). After the development of the retinal vascular system, three layers of vascular plexus are differentiated in the GCL, IPL, and OPL, respectively called superficial vascular plexus, intermediate vascular plexus, and deep vascular plexus. And the growth rate of the deep is preferred to the middle (Fruttiger, 2007). (2) Choroid vasculature also consists of three blood plexuses. The outermost plexus is called Haller's layer, the middle one is the Sattler layer, and the innermost anterior is the capillaries (Lutty and McLeod, 2018). The anterior capillaries allow plasma to congregate the surface of Bruch's membrane, and vesicles in RPE deliver nutrients and oxygen from plasma to the rod and cone.

Pathological angiogenesis is the leading irreversible cause of blindness among potentially blinding eye diseases. Angiogenesis is a process defined as forming new blood vessels on basis of existing capillaries under the combined action of angiogenic factors and endothelial cells. Endothelial cells consolidate their proliferation and transferability under the action of vascular endothelial growth factor (VEGF), insulin like growth factor 1 (IGF1) and Notch family receptors and their ligands; some endothelial cells grow the filopodia and become endothelial tip cells (Gerhardt et al., 2003; Cao et al., 2017). Mature neovascularization connects with the initial vessels to participate in blood circulation and become a section of the vascular system (Zoya Tahergorabil, 2012). In multiple retinal diseases, such as RAP, the neovascularization extending to the avascular area aggravated vision loss in patients (Spaide, 2013). And the activated microglia are involved in angiogenesis during disease onset.


### 2.2.3. BRB

BRB is vital to retinal function. Sharing resemblances with the blood-brain barrier in the brain, BRB protects the retina and isolates pathogens and microorganisms. The BRB consists of the inner blood-retinal barrier (iBRB) and the outer blood-retinal barrier (oBRB). Endothelial cells in the iBRB safeguard the integrity of the iBRB under the action of the neurovascular unit formed by microglia, Müller cells, astrocytes and pericytes (O'Leary and Campbell, 2021). And the oBRB is composed of choroid, Bruch's membrane and RPE (Figure 2B).

In angiodynamic researches, fluorescence angiography (VFA) is commonly utilized to examine the half-rise, half-fall and offset time of blood flow filling in retinal arteries, veins and capillaries after intravenous injection of drugs to check the damage of the blood-retinal barrier, vascular leakage and angiogenesis (Hui et al., 2014).

### 2.2.4. Microglial relationship with retinal vasculature


Microglia settle in the retina through the optic nerve, vitreous body, and ciliary body before retinal vasculature matures (Diaz-Araya et al., 1995). Their ramifications contact endothelial stalk cells and filopodia on tip cells in the period of mouse retinal vasculature development (Checchin et al., 2006). And microglia may lead tip cells to clarify the direction of neovascularization which is ultimately limited in retinal GCL, IPL and OPL layers (Haupt et al., 2019). Sharing resemblances with the brain, after treatment with lipopolysaccharide, the primary microglia up-regulate the VEGF-A and PDGF-BB expression level of RMEC which promotes the ability of tubes formation, migration and proliferation (Li et al., 2014; Ding et al., 2018). After using PLX5622 to deplete microglia, retinal



choroidal vessels begin to atrophy, and RPE present dysfunction (Yang et al., 2020). Microglia and retinal vessels are positively correlated in terms of quantity during development (Checchin et al., 2006; Zeng et al., 2022). The diminished number of retinal microglia result in sparse vascular density during the second and fourth postnatal days in *CSF<sup>-/-</sup>* deficient mice (Rymo et al., 2011). Exogenous microglia within intravitreal injection promotes the decreasing density and area of vascular triggered by resident microglia depletion during the retina development process (Checchin et al., 2006). Activated pro-inflammatory microglia are involved in the remodeling of retinal vasculature in the PKD model (Chen et al., 2021). This evidence is sufficient to demonstrate the indispensable role of microglia in adjacent retinal vasculature (Figures 3A–D).

### 2.2.5. Microglial relationship with BRB

Altered endothelial cell permeability is the central mechanism of BRB dysfunction during retinopathy (Sun et al., 2021). The defective BRB accelerates the death of the cone leading to swift vision degeneration (Ivanova et al., 2019). Targeting activated microglia is a crucial factor in repairing damaged BRB. They recruit neutrophil infiltration, aggravating the damage to the blood-retina barrier and optic nerve cell death in the retinal vein occlusion model (Jovanovic et al., 2020). Microglia can be activated by hyperglycemia in the retinal environment (Zhang et al., 2019). And the activated microglia engulf endothelial cells which exacerbates the phenomenon of acellular capillaries and albumin leakage in the diabetic model (Xie et al., 2021). Inflammatory factors secreted by activated microglia aggravate the damage of BRB (Usui-Ouchi et al., 2020).



Pro-inflammatory microglia activate the *TLR4/MyD88/NF- $\kappa$ B p65* signaling axis and the *NF- $\kappa$ B p65* nuclear translocation promotes the inflammatory factors resulting in the BRB breakdown (Fang et al., 2021). In the co-culture system, unstimulated microglia promote the expression of endothelial tight junction protein (TJP), Zonula Occluden-1 (*ZO-1*) and *Occludin* (Mehrabadi et al., 2017). However, activated microglia secrete IL-1 $\beta$  which stimulates VEGF releasing; subsequently, *VEGF* can down-regulate the expression of *ZO-1* and *Claudin-5* in endothelial cells in hypoxia conditions (Inada et al., 2021). And the ablation of activated microglia alleviates innate immunity stimulated by LPS and protects retinal BRB integrity through up-regulating *Occludin*, *ZO1* and *Claudin-5* (Kokona et al., 2018; Figures 3E–H).


In conclusion, activated microglia produce inflammatory factors and participate in the damage of BRB. In the hypoxia condition, microglia assist neovascularization and guide them incorrect positioning which causes the secondary lesions and accelerates the disorder progression in patients. Therefore, profoundly investigating the characteristics of microglia under pathological conditions may become a key to treating retinal diseases. After this, we choose one system and two targets we are more interested in. They contribute to retinal vasoconstriction, neovascularization and microglial cytoactive.

### 3. Potential targets of microglia in retinopathy

#### 3.1. The microglial renin-angiotensin system contributes to retinal vasoconstriction and angiogenesis

Renin-angiotensin system was initially considered a humoral system that governed blood pressure and water-sodium homeostasis. In recent studies, researchers find that renin-angiotensin system has the function of regulating ocular circulation and balancing intraocular pressure. The upregulation of the renin-angiotensin system contributes to the formation of blood vessels in the developing retina (Sarlos and Wilkinson-Berka, 2005). Dysregulation of the renin-angiotensin system is commonly seen in retinopathy, such as ROP. Blocking the renin-angiotensin system could postpone neovascularization forming (Misrak Tadesse et al., 2001).

In the renin-angiotensin system, renin, a rate-limiting enzyme which the precursor is pro-renin, disassembles angiotensinogen (*Agt*) encoded by the *AGT* gene to angiotensin I (*Ang I*). *Ang I* subsequently hydrolyze to effector molecule angiotensin II (*Ang II*) under angiotensin-converting enzyme (*ACE*). In the model of proliferative Diabetic



Retinopathy (DR) and Age-Related Macular Degeneration (AMD), *Ang II* upregulates the secretion of angiogenic factors and growth factors, provokes microglial activation and leads to hypertension (Moravski et al., 2000; Shi et al., 2010; Hatzopoulos et al., 2014). And up-regulating the expression of retinal *Ang II* promotes the expression of *TNF- $\alpha$*  secreted by the activated glial cells which contributes to the death of RGC (Jeon et al., 2022). Activated microglia secrete *Agt* and *Ang II* resulting in angiogenesis during tissue injury or disease (Mills et al., 2021).

However, the functions are dissimilar when *Ang II* binds with various receptors. The common receptors of *Ang II* are angiotensin subtype-1 receptor (*AT1R*), *Ang II* type 2 (*AT2R*) and *MAS-R* (Figure 4A).

### 3.1.1. Renin-angiotensin-aldosterone (RAAS) and *AT1R*

The human retina has locally subsisting RAAS systems (Wagner et al., 1996). RAAS controls vasoconstriction, regulates the release of vascular endothelial growth factor (*VEGF*) to participate in angiogenesis and increase vascular permeability. Moreover, *AT1R*, as an essential receptor with cardiovascular homeostasis, facilitates the efficacy of *Ang II*. And *Ang II* participates in aldosterone release under the action of aldosterone synthase (Maning et al., 2017). Aldosterone further binds to mineralocorticoid receptor (*MR*) regulating internal water-electrolyte balance and influencing cardiovascular diseases (Waanders et al., 2011). In addition, the aldosterone with the intravitreal injection can mimic clinical symptoms of central serous chorioretinopathy (CSC; Yu et al., 2022).

Retinal microglia have RAAS. In healthy conditions, Microglial *CX3CR1* receives neuronal *CX3CL1* signal which may govern the velocity of retina blood flow through RAAS (Mills et al., 2021;

Figure 4B). When the exogenous *Ang II* binds to *AT1R* on the surface of N9(a microglia cell line) and primary microglia, the *ROCK* activation stimulates the *NOX* activation via *P38* (Rodriguez-Perez et al., 2015). *NOX* is one of *ROS* manufacturers which facilitates the process of retinopathy (Ahmad et al., 2021). In addition, the binding of *Ang II* to *AT1R* motivates the translocation process of *NF- $\kappa$ B* and *STAT3* which accelerates the *TNF- $\alpha$*  releasing (Abadir et al., 2011). Adding *AT1R* antagonist effectively reverses microglial inflammatory phenotype and reduces the release of inflammatory factors stimulated by exogenous *Ang II* (Phipps et al., 2018). *AT1R* up-regulates at 12 h after ischemia, the candesartan, as an *AT1R* antagonist, effectively reduces the inflammation (Fukuda et al., 2010). The *AT1R* antagonist diminishes *NF- $\kappa$ B* nuclear translocation and *STAT3* phosphorylation which declines the release of *TNF- $\alpha$* , *IL-10*, *ROS* and nitrite accumulation in BV2 microglia treated with LPS (Bhat et al., 2016).

Microglia also express *MR* and aldosterone synthase. Microglial density significantly up-regulates in both REN-2 transgenic rats (rats overexpress renin and *Ang II*) and the Oxygen-Induced Retinopathy(OIR) model; Valsartan (an antagonist of *AT1R*) and Spironolactone (an antagonist of *MR*) effectively diminish the *VEGF*, *CCL5* and *IFN- $\gamma$*  secreted by the primary microglia *in vitro* hypoxia condition (Rana et al., 2020). Activated microglia can promote retinal neovascularization in some cases (Hatzopoulos et al., 2014). Using FAD286 (an aldosterone synthase inhibitor) reduces the density of *Iba1*<sup>+</sup> microglia and inhibits approximately 89% of neovascularization and 67% of neovascular tufts in the OIR model (Deliyanti et al., 2012).

According to the clues above, we can summarize microglia may regulate the velocity of retina blood flow through RAAS in healthy conditions. However, in chronic diseases, RAAS converts microglia to the pro-inflammatory phenotype, which releases inflammatory factors

and injures the integrity of BRB. Reactive microglia promote angiogenesis when the survival environment situates in relative hypoxia.

### 3.1.2. Ace/Ang II/AT2R

The *ACE/Ang II/AT2R* signaling pathway is associated with anti-angiogenesis, anti-inflammatory and partly balances the influence of RAAS (Tao et al., 2016; Carey, 2017). The expression of *AT2R* decreases with age and is lower than *AT1R* in the adult mouse retinas (Yoon et al., 2016; Verma et al., 2019). The up-regulation of *AT2R* effectively prevents damage to the optic nerve and the polymorphism of G/A at the 1,675 site may be related to arteriolar diameter (Kurihara et al., 2006; Liu et al., 2011). Moreover, the activation of the *AngII-AT2R* signaling pathway can reverse the microglial inflammatory phenotype (Gao W. et al., 2022).

Utilizing exogenous *Ang II* activates the *GSK3 $\beta$*  through upregulating the phosphorylation of Y216 and downregulating the phosphorylation of S9 which degrade the *NRF2* expression and inhibit microglial antioxidant capacity; the escalation of *Ang II* concurrently leads to mitochondrial dysfunction through stimulating phosphorylation of *PKC $\alpha/\beta$*  and *P-PKC $\delta$* , activating phosphorylation of *NOX-2<sup>p47<sup>phox</sup></sup>* and generating ROS accumulation (Bhat et al., 2019). *AT2R* binding to *AngII* stimulates the activation of *PP2A* (Guimond and Gallo-Payet, 2012). *PP2A* guarantees neuronal survival and silences *PKC/ERK/NF- $\kappa$ B* signaling pathway to prevent inflammatory cascade reaction stimulated by LPS (Egger et al., 2003; Bononi et al., 2011). CGP42112A, as an *AT2R* agonist, induces *PP2A* activation by declining the *p-Y307-PP2A* expression and inhibits *NOX-2* activation by declining the *P-S345-P47<sup>phox</sup>* expression; in addition, CGP42112A reduces the ROS production induced by *Ang II* and converts microglial phenotype from pro-inflammatory to anti-inflammatory (Bhat et al., 2019). Delaying administration of C21 (an agonist of *AT2R*) after 3 days post-stroke aggrandizes the number of anti-inflammatory microglia and effectively improves the rate of survivability, sensorimotor and cognitive deficits (Jackson et al., 2020; Sumners et al., 2020). Adding CGP42112 boosts the proliferation ability of microglial; the newborn cells predominantly present the ramified structure in peripheral infarct and the area of the infarct is diminished after 3 days of stroke; however, using PD4123319 (an *AT2R* antagonist) reverses the protective function of CGP42112 (McCarthy et al., 2012). We speculate that CGP42112 may promote anti-inflammatory microglia which maintain neuronal survivability. And in the central infarct core, the continuous release of inflammatory factors stimulates microglia to form different phenotypes with microglia in the peripheral infarct area. Whereafter, McCarthy et al. find that under the C21 stimulation, microglia releases brain derived neurotrophic factor (*BDNF*) which protects neuron survival and improves vasodilation (McCarthy et al., 2014). In addition, the upregulation of *VEGF* stimulated by PD123319 promotes the proliferation and migration ability of endothelial cells; on the contrary, CGP42112A selectively inhibits vascularization driven by *VEGF* in the OIR model (Carbajo-Lozoya et al., 2012).

Therefore, we speculate there may be a similar mechanism to brain-derived microglia in retinal microglia. Retinal microglia may preserve neuronal survival and blood vessels through the *ACE/Ang II/AT2R* signaling pathway which is expected to treat neovascular retinopathy.

### 3.1.3. ACE2/Ang1-7/MasR

*ACE2/Ang-(1-7)/MasR* promotes vasodilation and has demonstrated anti-inflammatory properties (Liu et al., 2016). *ACE2*, a homolog of *ACE*, hydrolyzes *Ang I* and *Ang II* to *Ang1-7*; *Ang1-7* binds to *Mas* receptor (*MasR*) which is encoded by *MAS1* proto-oncogene

(*Mas1*; Jiang et al., 2013). In oxidative stress injury induced by *Ang II*, the *Ang1-7* activation protects the survival of dopaminergic neurons, alleviates microglia-induced inflammatory responses and enhances the survival rate of hypertensive stroke rats model (Regenhardt et al., 2014; Liu et al., 2016; Costa-Besada et al., 2018).

Retinal microglia express *MasR* which gradually decreases with age (Tuhina Prasad and Li, 2014). In primary retinal microglia, the expression of *MasR* is up-regulated following the hypoxia condition which is a necessary element to stimulate angiogenesis in retinal development process (Gariano and Gardner, 2005; Foulquier et al., 2019). In *MAS1* deficient mice model, the rate of angiogenesis is slower than in controls, and the number of perivascular microglia and filopodia of endothelial tip cells is significantly decreased; under the stimulating of *MAS* agonist AVE0991, the mRNA expression level of *IL-10*, *Notch1*, *Dll4*, and *Jag1* are increased (Foulquier et al., 2019). The contact points between microglial ramifications and endothelial cells activate the *Notch1* signal which facilitates tip cells to recruit microglia during retinal development in newborn mice (Outtz et al., 2011). Microglia can stimulate vessel sprouting and branching of aortic ring explants through soluble factors and angiogenic factors; in turn, aortic ring explants recruit microglia to migrate toward them (Rymo et al., 2011). Therefore, we have reasonable doubt to suspect that microglia interact with endothelial cells and guide the tip cells in the neovascular to migrate toward the retinal periphery through the *MAS* signaling pathway during retinal development (Figure 4C).

The primary microglia of the brain also express *MasR* (Rivas-Santisteban et al., 2021). Nevertheless, renin-angiotensin system becomes unbalanced under the long-term stimulation of LPS in the brain; when *ACE2/ Ang(1-7)/MasR* signal axis is stimulated by AVE0991, microglia convert their phenotype from pro-inflammatory to anti-inflammatory (Dang et al., 2021). Utilizing DIZE, an *ACE2* activator, diminishes inflammation of activated microglia, up-regulates cell survival proteins and down-regulates neuronal apoptotic proteins through stimulating the *ACE2/ Ang (1-7)/MasR* signal axis in the 6-OHDA induced Parkinson's model; nevertheless, the A-779, a *MasR* antagonist, balances the protective affection of DIZE (Gupta et al., 2022). *MasR* can form a dimer with *AT1R* or *AT2R*. The expression of these dimers in striatal microglia is higher than those in cerebral neurons; when microglia are treated with *IFN- $\gamma$*  and LPS, the expression of *AT1R-MasR* is up-regulated and the expression of *AT2R-MasR* is down-regulated; Rivas et al. propose the possibility of forming heterotrimer among *AT1R*, *AT2R* and *MasR* (Rivas-Santisteban et al., 2021).

Based on the above clues, we consider the dysfunction of the microglial renin-angiotensin system loses the ability to control retinal vasoconstriction in retinal vascular malformation diseases which reduces the adequate oxygen supply to retinal neurons leading to the deterioration of vision. The molecular relationship among *AT1R*, *AT2R*, and *MasR* needs to be further verified in retinal microglia (Figure 4).

## 3.2. Microglial CD39 may provide anti-inflammatory treatment and protect BBB integrity during retinopathy

In the mammalian retina, ATP and adenosine (*ADO*) are crucial molecules that participate in vascular remodeling and form the neurovascular coupling (Zeiner et al., 2019; Losenkova et al., 2022). Abnormally elevated expression of ATP is a common phenomenon in many retinopathies. There are an abundant supply of adenosine



triphosphate (ATP) ecto-nucleotidases near retinal blood vessels which are classified into three main types: nucleoside triphosphate diphosphohydrolase 1 (*NTPDase1/CD39*), *NTPDase2* and ecto-5'-nucleotidase (*CD73*). Thereinto, *CD39* is an extracellular enzyme encoded by *ENTPD1* which hydrolyzes ATP to adenosine diphosphate (ADP) and adenosine (ADO) by cooperating with *CD73*. And retinal *CD39* are mainly produced by microglia and endothelial cells. At the early stage of retinopathy, the *CD39* expression is significantly up-regulated to maintain the balance between ATP and ADO; when retinal disease develops in the advanced stage, the number of *CD39*<sup>+</sup> microglia decrease prominently and the balance between ATP and ADO is broken; The overlaid ATP in the retinal microenvironment mediate inflammatory reaction that leads to neuronal death and M1 microglial activation (Lu et al., 2015; Hu et al., 2017; Rodrigues-Neves et al., 2018).

In addition to eliminating the redundant ATP in the internal environment, *CD39* can remodel the anti-inflammatory properties of macrophages (Villacampa et al., 2015; Jakovljevic et al., 2019). *CD39* and *CD73* synergistically inhibit the multiplication capacity of T cells and decrease the production of inflammatory factors in the EAU mouse model (Chen et al., 2016). Similarly, in type I diabetic hypothalamus, the expression of *CD39* in microglia and blood vessels is diminished by 30%, and the integrity of the blood-brain barrier is impaired; Minocycline can effectively promote the expression of *CD39* and the pro-inflammatory microglial activation is decreased (Bulavina et al., 2013; Hu et al., 2015).

The ADO, the hydrolysate of ATP, participates in the microglial contracting branches process and recruits them to migrate toward the lesion area (Matyash et al., 2017; Lim et al., 2018). The microglia migration capacity decreases significantly in *CD39*-deficient mice; after adding exogenous ecto-nucleotidases or ADO, microglial migration ability recovered (Farber et al., 2008). Microglial *CD39* mitigates neuronal overactivation through the ATP/AMP/ADO/AIR signaling axis (Badimon et al., 2020). ADO can bind to different receptors and perform different functions. Adenosine A1 receptor (*A1R*) and *A2aR* are involved in regulating angiogenesis, blood flow rate and inflammatory response. For example, in the diabetic retina, the ADO releasing and formation stimulated by Triamcinolone promotes the *A1R* activation which prevents cells from osmotic swelling and results in ion efflux through potassium and chloride channels (Wurm et al., 2008). And the *A2aR* activation can inhibit phagocytic activity and migration capacity of primary microglia (Ingwersen et al., 2016). The downstream response mechanism of retinal microglia receiving ADO signals is still unclear and needs further exploration (Figure 5A).

Interestingly, microglia create a spatially arranged network in the retinal parenchyma and form a local "purinergic junctions" system with *CD39*<sup>low</sup>/*CD73*<sup>-</sup> neuronal cell bodies and *CD39*<sup>high</sup>/*CD73*<sup>-</sup> retinal blood vessels through their *CD39*<sup>high</sup>/*CD73*<sup>low</sup> branches (Losenkova et al., 2022). Further exploring the mechanisms through which a broad spectrum of soluble and membrane-binding enzymes synergistically regulates purine levels in the retina may serve as potential therapeutic targets for the




FIGURE 5

Schematic diagram of partly signal pathways in retinal microglia. (A) Microglia express *CD39* and *CD73* that progressively hydrolyze ATP to ADO together. (B) In the OIR model, microglial necrosis promotes the leakage of FGF, which stimulates retinal neovascularization. Microglia express proangiogenic factors to promote retinal vascular proliferation, and the binding of (C) In the IR model, a competing endogenous RNA network (ceRNET) stimulates microglial pyroptosis. The maturation of pro-caspase1 in inflammasome and the activation and assembly of *GSDMD* proteins lead to the leakage of inflammatory factors, which ultimately result in the apoptosis of retinal neurons and damage to the BRB. The switching status of microglial signal pathways in different retinal environments and the target genes in upstream and downstream need to be further explored.

treatment of retinopathy (Zeiner et al., 2019). Increasing the number of CD39<sup>+</sup> microglia subset may contribute to the restoration of the retinal barrier and alleviate inflammation and reduce retinal vascularization.

### 3.3. Microglial Tgfb1 and its receptor TβRII involve in vascular remodeling and cellular phenotype conversion

Transforming growth factor beta (*Tgfb*), as a multifunctional cytokine which is associated with AMD susceptibility, is vital to sustain the specificity of microglia, ensure the stability of retinal vascular endothelial cells and BBB (Walshe et al., 2009; Braunger et al., 2013; Bohlen et al., 2017; Zarkada et al., 2021). *TGFB* can up-regulate *SNAIL* through AKT and polarize macrophages to anti-inflammatory phenotype; when blocking *TGFB/SNAIL* signal transduction, they promote the output of inflammatory factors and convert their phenotype to pro-inflammatory (Zhang et al., 2016). The *Tgfb* up-regulation inhibits pro-inflammatory microglial activation and reduces the *TNF-α* and *IL-6* releasing in microglia during retinopathy (Kim et al., 2004; Taylor et al., 2017; Yang et al., 2021).

In mammals, three members of the *Tgfb* isoform family encoded by independent genes are identified: *Tgfb1*, *Tgfb2* and *Tgfb3* (Anderson et al., 1995). *Tgfb1*, as a potential therapeutic target, reduces microglia-mediated neuroinflammation and improves outcomes of intracerebral hemorrhage after acute injury (Taylor et al., 2017). Although the expression of *Tgfb1* is the lowest one of the *Tgfb* family in the adult retina, the ability of *Tgfb1* has been proven to induce microglial conversion from the pro-inflammatory phenotype to anti-inflammatory phenotype which is related to neuroprotection and the anti-inflammatory treatment (Tosi et al., 2018; Caruso et al., 2020). In *Rho*<sup>-/-</sup> and *PDE6β*<sup>mut/mut</sup> mouse model of retinitis pigmentosa, AAV8-mediated supplementation of *Tgfb1* effectively prolongs the cone degeneration time through up-regulating *Spp1* and down-regulating *Gas6* of microglia, thereby indicating the therapeutic potential of precisely polarizing pro-inflammatory to anti-inflammatory microglia (Wang et al., 2020). And *Tgfb1* can also promote the up-regulation of CD73, inhibit the proliferation of activated T cells and reduce inflammation of the internal environment in the EAU model (Chen et al., 2016). Surprisingly, *Tgfb1* expressed by microglia frequently associates with vascular remodeling. In the microglial autocrine *Tgfb1* signaling pathway, *Kindlin3*, as an intracellular adapter molecule, is associated with microglial polarization; when *Kindlin3* is knockout, high myosin contractility contributes to *ERK* phosphorylation and further promotes the overexpression of *Tgfb1* which results in angiogenesis (Dudiki et al., 2020).

The *Tgfb* receptor consists of two structurally similar sub-families (*TβRI* and *TβRII*) and a transmembrane proteoglycan (*beta-glycan/TβRIII*). Thereinto, *TβRII* belongs to the serine and threonine transferase receptor, which is highly expressed in retinal microglia and endothelial cells (Ma et al., 2019). After *Tgfb* ligation to *TβRII*, *SMAD2* and *SMAD3* are phosphorylated and form complexes with *SMAD4* which transfer to the nucleus and further promote the transcription of target genes (Javelaud and Mauviel, 2004). In *TβRII*-deficient condition, the retina presents a critically pathological change in structure and function, such as the shortage of pericyte differentiation and retinal capillaries, which leads to microaneurysms, hemorrhages, microglial activation and proliferative retinopathy (Braunger et al., 2015). According to the collaborative genome-wide association study, *TβRII*,

as a receptor for *Tgfb* signaling pathway, was also associated with AMD susceptibility (Fritsche et al., 2013).

Nevertheless, because of the postnatal lethality of *TGFB1*-deficient mice or lethal embryonic phenotypes of *TβRII*-deficient mice, was limited to investigate how *TGFB1* regulates microglial activation through *TβRII* in adults (Shull et al., 1992; Oshima et al., 1996). Therefore, Zoller et al. constructed *Cx3cr1*<sup>CreERT2</sup>;*Tgfb2*<sup>fl/fl</sup> mouse model to persuade the conditional deletion of *TβRII* in adult microglia and found that *TβRII*-deficient microglia change the original morphology, up-regulate microglial activation and increase phosphorylation of *TAK1* (Zoller et al., 2018). The ablation of *TβRII* in retinal microglia induces the secondary apoptosis of Müller and reduces mRNA expression level of microglial 'sosome' transcripts, such as *Siglech* (Hickman et al., 2013; Ma et al., 2019). Although *TβRII*-deficient microglia do not induce obvious changes in the retinal structure of adults, they promote pathological angiogenesis after laser injury (Ma et al., 2019). Similarly, in OIR, *TβRII*-deficient microglia secrete chemokines and up-regulate *Igf1* expression which exacerbates retinal neovascularization plexus forming (Usui-Ouchi et al., 2022; Figure 5B).

According to these shreds of evidence, we draw partly microglial signaling pathways we are more interested in (Figure 5). Then we speculate that retinal *TGFB1* promotes the up-regulation of CD73; CD39 in microglia or endothelial cells cooperates with CD73 to hydrolyze *ATP* to *ADP* and *ADO*; and the hydrolysis production *ADO* can recruit microglia. In retinal vascular diseases, such as diabetic retinopathy and retinopathy of prematurity, the expression of *ATP* and *ADO* are upregulated. This may partly explain why microglia appear in adjacent vessel and injury sites. Intracellular molecular mechanisms in microglia responding to *ADO* need to be explored in depth. In addition, the *Tgfb1/TβRII* signaling pathway in microglia effectively decreases microglial activation and exhibits a protective effect on neurons in retinopathy. And the disruption of the *Tgfb1/TβRII* signaling pathway in microglia accelerates pathological angiogenesis during retinal injury and hypoxic processing. The relevance of *Tgfb1* to microglia CD39 and the renin-angiotensin system is currently unknown.

## 4. Effect of microglia on retinal vasculature and BRB in various retinopathy models

### 4.1. Microglia in diabetic retinopathy

DR, characterized by the apoptosis of pericytes and endothelial cells as an early clinical feature, results in the damage of BRB integrity and leakage of plasma. Although microglia may be a member of the BRB and act as a secondary protective barrier for extravasated proteins, we cannot ignore the inflammatory response induced by activated microglia. Microglia is the main source of retinal *TNF-α* after retinal injury. At 3 h of *TNF-α* intravitreal injections, endothelial cells appeared necrotic and revascularization began at 24 h injection (Claudio et al., 1994). The massive *IFN-γ* and *IL-6* in DR activate microglial *STAT3* phosphorylation which stimulates *TNF-α* secretion, suppresses the kinase activity in *AKT/p70S6* signal axis and leads to the apoptosis of pericytes. Under *IL-6* stimulation, the activated microglia recruit to the vicinity of RPE and secrete *TNF-α* to downregulate the expression of *ZO-1* and *Occludin* in the RPE which disrupt the integrity of oBRB; whereas using *STAT3* inhibitors modify the influence of microglia to RPE (Jo et al., 2019). With a similar

mechanism, the activated microglia increase the permeability of endothelial cells in iBRB (Yun et al., 2017).

In addition, the normal retina responds to light stimulation through neurovascular coupling which expands the blood flow per unit time; whereas in the early stages of type I and II diabetes mellitus, patients normally present a deferred reaction under the stimulation of flickering (Lim et al., 2014). Microglial branches contact the pericytes, endothelial cells, and neuronal synapses in the retinal vasculature and regulate retinal vasoconstriction through the renin-angiotensin system; nevertheless, microglia lost this ability in the early STZ-induced mouse model (Mills et al., 2021). Asiatic acid upregulates the protein arginine (*Arg-1*) expression and reduces *NF- $\kappa$ B p65* nuclear translocation in microglia; the microglial phenotype is reversed and alleviates the disease process of DR (Fang et al., 2021). Erythropoietin protects the BRB by increasing phosphorylation of the *Src/Akt/cofilin* signaling axis to inhibit microglia engulfing endothelial cells (Xie et al., 2021). CD5-2, as a novel oligonucleotide-based drug, enlarges the VE-cadherin transcription which is silenced by *miR-27a* in endothelial cells and defends the integrity of BRB and preserves the coverage of pericytes; the activation state of microglia is suppressed after treatment with CD5-2 (Ting et al., 2019). Melatonin can inhibit microglia activation through the *PI3K/Akt/Stat3/NF- $\kappa$ B* signal axis and protect pericytes from apoptosis (Tang L. et al., 2022). And *MicroRNA-93-5p* can restrain M1 microglia activation by silencing *STAT3* (Wang et al., 2021).

## 4.2. Microglia in age-related macular degeneration

AMD is a neurodegenerative disease of retinal macular degeneration which is associated with age and can mainly divide into three types: (1) Geographic atrophy; (2) choroidal neovascularization; (3) retinal angiomatous proliferation (RAP). In healthy human retinas, the macular region has no blood vessels on account of the abundantly antiangiogenic factors expressed by cells (Lutty and McLeod, 2018). And the high density of cones in this area indicates more susceptibility to oxidative stress.

Quite unlike humans, the retina of mice does not have macular structures. Hence, external assistance is needed to establish disease models and explore the mechanisms involved in macular degeneration. For example, the NRL-deficient transgenic model assists us in researching retinal degenerative diseases related to cones and decreases the interference of rods (Samardzija et al., 2014). Barben et al., based on this model and knocked out the von Hippel Lindau protein to mimic the degenerative death mechanism of cone under chronic hypoxic conditions in AMD and found that microglia infiltrate to the fundus and the upregulation of *HIF-1A*, *VEGF*, and *Fgf2* related to neovascularization during early retinal development (Barben et al., 2018). In contrast, the sterile 1% NaIO<sub>3</sub> can mimic geographic atrophy by injecting the tail vein (Enzbrenner et al., 2021). And in the 5XFAD mouse model, the presence of deposits on the fundus can mimic types 2 and 3 AMD while using the low-dose efavirenz reduces microglial activation, neovascular formation, and accumulations of amyloid  $\beta$  plaques in focus (El-Darzi et al., 2022).

The microglial number in perivascular and subretinal increases with age. The increased number of microglia and lipofuscin deposition synergistically contribute to the risk of the AMD process (Xu et al., 2008). And the structurally altered *HTRA1* contributes to the *Tgfb $\beta$*  signaling in autocrine microglia which downregulates phosphorylation of *SMAD2* and similarly increases the risk of AMD

(Friedrich et al., 2015). Moreover, the high-fat diet activates the immune response of retinal microglia; *IL-1 $\beta$*  released by the activated microglia provokes the cellular iron sequestration reaction which sparks the toxic accumulation of iron in RPE cells; subsequently, the RPE presents oxidative stress and electrophysiological dysfunction facilitating the process of AMD (Sterling et al., 2022).

## 4.3. Microglia in other types of retinal diseases

Autoimmune uveitis (Au) is a chronic inflammatory intraocular disease mediated by the autoimmune system. In AU, the abnormal activation of microglia increase the production of inducible nitric oxide synthase (*iNOS*) which accelerates retinal degeneration and the loss of iBRB integrity, the leakage and abnormal proliferation of capillaries. In the EAU mouse model, the addition of Icaritin upregulates *PRDX3* which transfers the microglia phenotype from pro-inflammatory to anti-inflammatory and alleviates the state of illness (Wang et al., 2022). Thereinto, *PRDX3*, a primary isoform of six peroxidases in mitochondria, swiftly scavenges abnormal accumulation of *H<sub>2</sub>O<sub>2</sub>* to decrease apoptosis and damage caused by oxidative stress (Rebelo et al., 2021).

In addition, CSC is characterized by the dilation and leakage of choroidal vasculature leading to the accumulation of subretinal fluid and serous detachment of the neurosensory retina which can mimic by using aldosterone with the intravitreal injection (Zhao et al., 2012; Yu et al., 2022). CSC may be associated with inappropriate activation of *MR* (Zhao et al., 2017). The melatonin through intraperitoneal injection rescues microglial infiltration mediated by activation of the *IL-17A/NF- $\kappa$ B* signaling pathway and significantly reduces *CX3CR1* and cyclooxygenase 2 secreted by the activated microglia in the CSC mouse model (Yu et al., 2022).

## 4.4. Microglia in oxygen-induced retinopathy (OIR)

Microglia are involved in neovascularization and are activated prior to neovascularization in the central avascular region during OIR (Ritter et al., 2006; Fischer et al., 2011). At the beginning of the OIR model construction, mice are exposed to an oxygen-rich environment and the capillaries appear to atrophy; when the survival environment returns to the normoxia, neovascularization occurs in the retina. At postnatal 12 days, the *NF- $\kappa$ B/STAT3* signaling pathway is activated in pro-inflammatory microglia which are presented in the central and peripheral neovascular plexus of the retina; and at postnatal 17 days, anti-inflammatory microglia gradually emerge (Li et al., 2021). During this period, the decreased number of microglia can exacerbate retinal vascular degeneration (Liu J. et al., 2022). Microglia activate the *RIP1/RIP3* signaling pathway to promote the phosphorylation of *MLKL* which translocate to the cytoplasmic membrane and regulates the activation of ion channels leading to necroptotic of microglia; the necrotic microglia release *FGF2* and *HIF-1A* which stimulate retinal neovascularization; and the knockdown of *RIP3* effectively alleviate angiogenesis (Kubota et al., 2009).

The deletion of *CCN1*, a gene that encodes the extracellular matrix-associated integrin-binding protein, exacerbates the pro-inflammatory responses of microglia and leads to the malformation of retinal vasculature in the OIR model (Yan et al., 2015). And the administration

of Celestrol reverses the activation of the *miR-17-5p/HIF-1 $\alpha$ /VEGF* signaling pathway which reduces retinal neovascularization by inhibiting the microglial activation and inflammation; the proliferation, migration and tube formation ability of human retinal microvascular endothelial cells are also inhibited *in vitro* culture (Zhao et al., 2022). In addition, KC7F2, a novel molecular compound, reduces retinal angiogenesis by reducing the co-localization ratio between microglia and neovascularization and inhibits the activation of the *HIF1 $\alpha$ /VEGF* signaling pathway in human umbilical vein endothelial cells (Tang X. et al., 2022).

#### 4.5. Microglia in ischemia–reperfusion (IR) model

The retinal IR model is another common disease model used in experiments to mimic glaucoma, DR and retinal arterial obstruction (Osborne et al., 2004). The activation of immune cells and cytokines can mediate the onset of inflammation and tissue damage; thereinto, microglia are also activated in the early injury process (Zhang et al., 2005). The permeability is quickly increased in vascular endothelial cells accompanied by a strong sterile inflammatory response leading to the BRB breakdown (Muthusamy et al., 2014). On the 13th day of modeling, the average thickness of the GCL and IPL layers decreases by 36 and 5% is reduced in OPL layers; on the 28th day, the overall retinal thickness diminishes by about 10% compared with the control; in addition, after 2 days of IR, the up-regulation of *Occludin pSer490* stimulates the *Occludin* degradation through ubiquitination predicting that TJs initiate hydrolysis in retinal endothelial cells and inflammation gradually subsides by the fourth week of IR modeling; the activated microglia engulf optic nerve cells and participate in vascular permeability; the administration of minocycline can improve the iBRB repair and reduce the abnormal activation of microglia in the early stage (Abcouwer et al., 2021).

Long non-coding RNA (lncRNA)-*H19* is a key target of IR-induced inflammation; lncRNA-*H19* reduces the *miR-21* and promotes the *PDCD4* expression in the competing endogenous RNA network which activates inflammasome; subsequently, the activated inflammasome prompt the *caspase-1* maturation and induce the microglial pyroptosis through *GSDMD* protein; Microglial *IL-1 $\beta$*  and *IL18* release to the retina and participates in inflammatory response (Wan et al., 2020; Figure 5C).

The inflammatory response from inappropriately activated microglia can exacerbate the retinopathy and the death of pro-inflammatory microglia at later stages is fatal to the disease. Therefore, transferring pro-inflammatory microglia to anti-inflammatory microglia is feasible (Table 1).

#### 5. Microglia and induced pluripotent stem cell (iPSC) technology

The advent of single-cell sequencing and fate mapping techniques promises to enlarge the understanding of microglial diversity and provide a novel vision of disease-related heterogeneity and plasticity of microglia responses (Elmore et al., 2014; Huang et al., 2018a,b). However, the specific genes in microglia are instantly down-regulated when transferred from vivo to the extracorporeal culture environment (Gosselin et al., 2017). Establishing induced pluripotent stem cell-derived microglia (iMG) provides a new effective method to explore the microglial characteristic in the pathological condition, regenerative

therapeutic and the intercellular co-relationship during the developing retina. iMG shows comparable signatures with purified human fetal microglia in the same culture condition which can respond to LPS and *IFN- $\gamma$*  stimulation and possess professional phagocytosis (Muffat et al., 2016). The iMGs cocultured with retinal organoids furnish a foundation for future research to investigate molecular signaling mechanisms (Bartalska et al., 2022).

In self-formed ectodermal autonomous multi-zone (SEAM), a two-dimensional model of human induced pluripotent stem cells of ocular cells, iMGs enhance the expression of *VEGF-A* under the stimulus of *Tgfb1* (Hayashi et al., 2016; Shiraki et al., 2022). Hematopoietic progenitor cells induced by pluripotent stem cells can be converted into iMGs and PSC-derived macrophages in different culture conditions; iMGs and their coculture with retinal organoids promote mutual differentiation; the differentiated iMGs migrate to the beneath photoreceptor cell layer under the coculture with retinal organoids and further differentiate into resident microglia which can promote the migration of photoreceptor precursors and may contribute to the function of pruning synapses; retinal organoids up-regulate pivotal genes which are related to development, such as *SIX3*, *SIX6*, *OTX2*, *HES1* and *DKK3* under the addition of iMGs (Gao M. L. et al., 2022). In addition, with the help of iMGs, Micklisch et al. discover that human microglia express the age-related maculopathy susceptibility 2 (*ARMS2*) transcripts which can cooperate with properdin and intensify the ability of complement activation to eliminate apoptotic and necrotic cells and its polymorphism is associated with AMD susceptibility (Micklisch et al., 2017). Similarly, iMGs, with the deficit of ADAM metalloproteinase domain 17 (*ADAM17*), present similar phenomena with *ADAM17<sup>-/-</sup>* *Drosophila* which leads to the accumulation of lipid droplet and the semblable clinical features is semblable with age-dependent degeneration of the retina (Mulyil et al., 2020).

Therefore, iMGs can be an effective reference that is vital to analyze the function of retinal microglia and potential therapeutic targets. The unique cellular properties of microglia may help retinal organoids build vascular networks.

#### 6. Perspectives

Following the deep reform in single-cell RNA sequencing technology, the exploration of new targets has also been effectively explored in these years and we have generated preliminary knowledge about microglia. For example, based on previous Rna-seq sequencing data, we know the macroglial subsets specifically express the diazepam-binding inhibitor (*DBI*) which can restore microglial inflammatory response to the baseline (Menon et al., 2019). Translocator Protein (*TPSO*) in microglia is upregulated after inflammation activation. And *DBI* negatively regulates microglial activation by binding to *TSPO* and limits the extent of the inflammatory responses at the onset which facilitates the regression of inflammation (Wang M. et al., 2014). *DBI-TSPO* signaling pathway exerts anti-inflammatory and neuroprotective effects which provide clues for the research of anti-*VEGF* drugs (Gao S. et al., 2022). Although intravitreal injection of *VEGF*-inhibiting drugs is a breakthrough treatment for retinal neovascularization, the therapy targeting *VEGF* is not widely available for all patients (Ip et al., 2015). And repeated injections of anti-*VEGF* drugs are a safety concern for high-risk patients including premature infants, diabetes, and cardiovascular diseases (Usui-Ouchi and Friedlander, 2019). Based on the findings of Liu et al., there is a subset of microglia associated with

TABLE 1 Potential drugs treat the damaged BRB and the retinal neovascularization.

Drugs	Simulation of disease	Study Model	Pathways	Main outcomes	References	
Melatonin	Acute glaucoma	Acute ocular hypertension	<i>Inflammasome/GSDMD RIP1-RIP3/MLKL</i>	↓ P-RIP3 And Iba1 <sup>+</sup> / IL-1β <sup>+</sup> microglia	Ye et al. (2022)	
				↓ Microglial pyroptosis and inflammation		
				↓ RGC: Caspase-3-dependent apoptosis		
	Central serous chorioretinopathy	Aldosterone	<i>IL-17A/NF-KB</i>	↑ Tight junction protein in BRB	Yu et al. (2022)	
				↓ Microglial infiltration		
				↓ Matrix metalloproteinases		
				↓ Inflammatory factors		
	Diabetic retinopathy	STZ	<i>PI3K/Akt/Stat3/NF-KB</i>	↑ Anti-inflammatory microglial	Tang et al. (2022)	
				↑ BRB function		
				↓ Pericyte loss		
				↓ iBRB leakage		
				↓ Activated microglial number		
	Retinitis pigmentosa	RD10	None	↑ The thickness of the ONL	Xu et al. (2017)	
				↑ Photoreceptor cells survival		
				↓ Müller cell gliosis		
				↓ Retinal inflammatory response		
	Retinopathy of prematurity	OIR	<i>HIF-1A/VEGF</i>	↑ The formation of tip cells	Xu et al. (2018)	
				↓ Vascular leakage		
↓ Pathological neovascularization						
↓ Microgliosis						
↓ Inflammatory factors						
Age-related macular degeneration	Laser	<i>RhoA/ROCK</i>	↓ Choroidal neovascularization	Xu et al. (2020)		
			↓ Vascular leakage			
			↓ Vascular proliferation			
Asiatic Acid	Diabetic retinopathy	STZ	<i>TLR4/Myd88/NF-KB P65</i>	↑ Tight junction protein in BRB	Fang et al. (2021)	
				↑ Anti-inflammatory microglia		
Erythropoietin	Diabetic retinopathy	STZ	<i>Src/Akt/Cofilin</i>	↑ Endothelial cells survival	Xie et al. (2021)	
				↓ Albumin leakage		
				↓ Microglial activation		
				↓ Microglial phagocytosis		
			None	↓ Reactive gliosis		McVicar et al. (2011)
				↓ Microglial activation		
				↓ The number of apoptotic cells		
				↓ Acellular capillaries		
	Retinitis pigmentosa	RD10	None	↑ Cone cell survival	Sasahara et al. (2008)	
				↓ Retinal degeneration		
				↓ Neurovascular degeneration		
	Polycystic kidney disease	PKD	None	↑ Retinal thickness	Busch et al. (2014)	
↓ Acellular capillaries						
↓ Microglial activation						

(Continued)

TABLE 1 (Continued)

Drugs	Simulation of disease	Study Model	Pathways	Main outcomes	References
	Inherited retinal diseases	RCS Rat	<i>p75<sup>NTR</sup>/pro-NT3</i>	<ul style="list-style-type: none"> <li>↑ Ramified microglial infiltration</li> <li>↑ CD34<sup>+</sup> cells</li> <li>↓ Retinal capillary dropout</li> <li>↓ Retinal gliosis</li> <li>↓ Focal vascular lesions</li> <li>↓ Reactive gliosis</li> <li>↓ Photoreceptor apoptosis</li> </ul>	Shen et al. (2014)
CD5-2	Diabetic retinopathy	STZ and OIR	<i>VE-cadherin/TGFβ and PDGF-β</i>	<ul style="list-style-type: none"> <li>↓ Pericyte dropout</li> <li>↓ Vascular leakage</li> <li>↓ Microglial activation in deep plexus</li> </ul>	Ting et al. (2019)
Efavirenz	Alzheimer's disease	5XFAD	None	<ul style="list-style-type: none"> <li>↑ Ramified microglia</li> <li>↓ Vascular lesion frequency</li> <li>↓ Vascular leakage</li> <li>↓ Focal accumulations of amyloid β plaques</li> <li>↓ Neovascularization</li> </ul>	El-Darzi et al. (2022)
Icariin	Experimental autoimmune uveitis	IRBP	<i>GPX4/SLC7A11/ACSL4</i>	<ul style="list-style-type: none"> <li>↑ The expression of PRDX3</li> <li>↑ Anti-inflammatory microglia</li> <li>↓ Retinal inflammation</li> </ul>	Wang et al. (2022)
	Diabetic retinopathy	STZ	None	<ul style="list-style-type: none"> <li>↑ The basal membrane thickness</li> <li>↑ Micro-vessel density</li> <li>↑ RGC neurite growth</li> </ul>	Xin et al. (2012)
Celastrol	Retinopathy of prematurity	OIR	<i>Mir-17-5p/HIF-1A/VEGF</i>	<ul style="list-style-type: none"> <li>↓ Microglial activation</li> <li>↓ Neovascularization</li> <li>↓ Inflammatory cytokine</li> </ul>	Zhao et al. (2022)
	Retinal degeneration	Bright light	None	<ul style="list-style-type: none"> <li>↓ Photoreceptor degeneration</li> <li>↓ Photoreceptor apoptosis</li> <li>↓ Oxidative stress</li> <li>↓ Inflammatory cytokine</li> <li>↓ Leukostasis</li> <li>↓ Microglial activation</li> <li>↓ Reactive gliosis</li> <li>↓ Proinflammatory genes</li> </ul>	Bian et al. (2016)
KC7F2	Retinopathy of prematurity	OIR	<i>HIF1A/VEGF</i>	<ul style="list-style-type: none"> <li>↓ Neovascularization</li> <li>↓ Endothelial cell proliferation</li> <li>↓ Retinal inflammation</li> <li>↓ Leukocytes and microglia</li> </ul>	Tang X. et al. (2022)
Progesterone	Inherited retinal diseases	Optic nerve crush	None	<ul style="list-style-type: none"> <li>↑ Anti-inflammatory microglia</li> <li>↓ Neuronal apoptosis</li> <li>↓ Astrocyte activation</li> <li>↓ Microglial proliferation</li> </ul>	Yang et al. (2021)
Norgestrel	Retinitis pigmentosa	RD10	<i>STAT3/GFAP</i>	<ul style="list-style-type: none"> <li>↓ Gliosis</li> <li>↓ Microglial cytokines release</li> </ul>	Roche et al. (2018)

(Continued)

TABLE 1 (Continued)

Drugs	Simulation of disease	Study Model	Pathways	Main outcomes	References	
	Retinitis pigmentosa	RD10	<i>CX3CL1-CX3CRI</i>	<ul style="list-style-type: none"> <li>↑ Neuroprotection</li> <li>↓ Microglial-derived toxicity</li> <li>↓ Microglial infiltration</li> </ul>	Roche et al. (2017)	
Minocycline	Retinitis pigmentosa	Rho <sup>-/-</sup>	None	<ul style="list-style-type: none"> <li>↑ Photoreceptor survival</li> <li>↓ Disease associated microglia</li> <li>↓ Microglial phagocytosis</li> </ul>	Ozaki et al. (2022)	
	Retinal vein occlusions diabetic retinopathy retinopathy of prematurity	IR model	None	<ul style="list-style-type: none"> <li>↑ iBRB integrity</li> <li>↑ Restoration of vascular barrier</li> <li>↓ Pro-inflammatory microglia</li> <li>↓ Retinal inflammation</li> </ul>	Abcouwer et al. (2021)	
				<ul style="list-style-type: none"> <li>↓ Vascular leakage</li> <li>↓ Retinal inflammation</li> <li>↓ Leukocyte adhesion</li> </ul>	Abcouwer et al. (2013)	
	Glaucoma	S100B	None	<ul style="list-style-type: none"> <li>↓ Neurofilament degeneration</li> <li>↓ Microglial activation</li> <li>↓ Inflammatory cell infiltration</li> </ul>	Grotegut et al. (2020)	
	Experimental autoimmune uveitis	IRBP	None	<ul style="list-style-type: none"> <li>↑ Retinal function</li> <li>↑ BRB INTEGRITY</li> <li>↓ Microglial Activation</li> <li>↓ Macrophage and leukocyte infiltration</li> <li>↓ Leukocyte adhesion</li> </ul>	Zhou et al. (2020)	
	Minocycline	Diabetic retinopathy	STZ	<i>Caspase-1/ IL-1β</i>	↓ Acellular capillaries	Vincent and Mohr (2007)
				None	<ul style="list-style-type: none"> <li>↓ Histone acetylation (AcH3K9, AcH3K18)</li> <li>↓ Müller cell activation</li> <li>↓ Retinal inflammation</li> </ul>	Wang et al. (2012)
None				<ul style="list-style-type: none"> <li>↓ IL-1β, caspase-3 activation</li> <li>↓ Retinal neuronal cell death</li> <li>↓ Microglial cytokines</li> </ul>	Krady et al. (2005)	
Age-related macular degeneration		Acute white light	None	<ul style="list-style-type: none"> <li>↑ Photoreceptor survival</li> <li>↓ Caspase-3/7 activation</li> <li>↓ Neurotoxicity</li> <li>↓ Microglial activation</li> <li>↓ Pro-inflammatory</li> <li>↓ Retinal degeneration</li> </ul>	Scholz et al. (2015)	
	Excitotoxicity	NMDA	None	<ul style="list-style-type: none"> <li>↓ Microglial activation</li> <li>↓ RGC degeneration</li> <li>↓ IL-1β, IL-6, TNF-α,</li> </ul>	Takeda et al. (2018)	
	Glaucoma	IOP	None	<ul style="list-style-type: none"> <li>↓ Microglial activation</li> <li>↓ RGC survival</li> <li>↓ CD68<sup>+</sup> microglia</li> </ul>	Wang K. et al. (2014)	
	Optic glioma	Nf1 <sup>flax/flax</sup>	<i>Estrogen/ ERβ</i>	<ul style="list-style-type: none"> <li>↑ The NFL thickness</li> <li>↓ Microglial activation</li> </ul>	Toonen et al. (2017)	

neovascularization during pathological retinal angiogenesis which expresses IGF1 (Liu Z. et al., 2022). This subset may be a breakthrough to treat proliferative diabetic retinopathy and retinopathy of prematurity. *CD39*, *Tgfb* and the renin-angiotensin system are undoubtedly potential molecular targets in terms of blocking microglia recruitment and reducing neovascularization. Hence, it is necessary to investigate the relevance of the three in retinopathy. Furthermore, we need to explore the microglial subset that induces blood vessel formation during normal retinal development, as such cells may contribute to vascularizing human retinal organoids. In addition, in the stem cell transplantation technology, the absence of microglia and chondroitin sulfate proteoglycans facilitate the migration of exogenous Müller; although the use of chondroitinase ABC and erythropoietin reduce inflammation to some extent, it still presents immune rejection at the fourth week of transplantation (Bull et al., 2008; Singhal et al., 2008). According to the RNA-seq data of Huang et al., the regenerated microglia after ablation show no significant up-regulation of inflammation-related genes (Huang et al., 2018a). Therefore, the two conjectures: stem cell transplantation technology combined with the melting regeneration properties of microglia and modified microglia for drug delivery to the retina are expected to be a promising treatment for retinal inflammation, alleviate angiogenesis and protect neurons and BRB.

Microglia have considerable potential as the only cells that can regenerate without limits in the steady-state environment of the retina. Microglia have been discovered for a century, but the mechanisms of molecular need to be further elucidated in detail.

## Author contributions

Original draft preparation was conducted by XF and SF. Writing, reviewing and editing was completed by HQ, LY, and KY. Visualization

and figure creation was completed by CZ. All authors contributed to the article and approved the submitted version.

## Funding

This work was supported by National Natural Science Foundation of China (no. 31970930), Hubei Natural Science Foundation (no. 2020CFA069, no. 2018CFB434), and Neuroscience Team Development Project of Wuhan University of Science and Technology (no. 1180002).

## Acknowledgments

We thank the members of Yao laboratory for their kind suggestion and technical assistance.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## References

- Abadir, P. M., Walston, J. D., Carey, R. M., and Siragy, H. M. (2011). Angiotensin II type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNF $\alpha$  production. *J. Interf. Cytokine Res.* 31, 471–474. doi: 10.1089/jir.2010.0043
- Abcouwer, S. F., Lin, C. M., Shanmugam, S., Muthusamy, A., Barber, A. J., and Antonetti, D. A. (2013). Minocycline prevents retinal inflammation and vascular permeability following ischemia-reperfusion injury. *J. Neuroinflammation* 10:149. doi: 10.1186/1742-2094-10-149
- Abcouwer, S. F., Shanmugam, S., Muthusamy, A., Lin, C. M., Kong, D., Hager, H., et al. (2021). Inflammatory resolution and vascular barrier restoration after retinal ischemia reperfusion injury. *J. Neuroinflammation* 18:186. doi: 10.1186/s12974-021-02237-5
- Ahmad, A., Nawaz, M. I., Siddiquei, M. M., and Abu El-Asrar, A. M. (2021). Apocynin ameliorates NADPH oxidase 4 (NOX4) induced oxidative damage in the hypoxic human retinal Müller cells and diabetic rat retina. *Mol. Cell. Biochem.* 476, 2099–2109. doi: 10.1007/s11010-021-04071-y
- Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W., and Rossi, F. M. (2007). Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. *Nat. Neurosci.* 10, 1538–1543. doi: 10.1038/nn2014
- Anderson, D. H., Guerin, C. J., Hageman, G. S., Pfeffer, B. A., and Flanders, K. C. (1995). Distribution of transforming growth factor-beta isoforms in the mammalian retina. *J. Neurosci. Res.* 42, 63–79. doi: 10.1002/jnr.490420108
- Anderson, S. R., Roberts, J. M., Ghena, N., Irvin, E. A., Schwakopf, J., Cooperstein, I. B., et al. (2022). Neuronal apoptosis drives remodeling states of microglia and shifts in survival pathway dependence. *elife* 11:76564. doi: 10.7554/eLife.76564
- Badimon, A., Strasburger, H. J., Ayata, P., Chen, X., Nair, A., Ikegami, A., et al. (2020). Negative feedback control of neuronal activity by microglia. *Nature* 586, 417–423. doi: 10.1038/s41586-020-2777-8
- Barben, M., Schori, C., Samardzija, M., and Grimm, C. (2018). Targeting Hif1 $\alpha$  rescues cone degeneration and prevents subretinal neovascularization in a model of chronic hypoxia. *Mol. Neurodegener.* 13:12. doi: 10.1186/s13024-018-0243-y
- Bartalska, K., Hubschmann, V., Korkut-Demirbas, M., Cubero, R. J. A., Venturino, A., Rossler, K., et al. (2022). A systematic characterization of microglia-like cell occurrence during retinal organoid differentiation. *iScience* 25:104580. doi: 10.1016/j.isci.2022.104580
- Bhat, S. A., Goel, R., Shukla, R., and Hanif, K. (2016). Angiotensin receptor blockade modulates NF $\kappa$ B and STAT3 signaling and inhibits glial activation and Neuroinflammation better than angiotensin-converting enzyme inhibition. *Mol. Neurobiol.* 53, 6950–6967. doi: 10.1007/s12035-015-9584-5
- Bhat, S. A., Sood, A., Shukla, R., and Hanif, K. (2019). AT2R activation prevents microglia pro-inflammatory activation in a NOX-dependent manner: inhibition of PKC activation and p47(phox) phosphorylation by PP2A. *Mol. Neurobiol.* 56, 3005–3023. doi: 10.1007/s12035-018-1272-9
- Bian, M., Du, X., Cui, J., Wang, P., Wang, W., Zhu, W., et al. (2016). Celastrol protects mouse retinas from bright light-induced degeneration through inhibition of oxidative stress and inflammation. *J. Neuroinflammation* 13:50. doi: 10.1186/s12974-016-0516-8
- Biesecker, K. R., Srien, A. I., Shimoda, A. M., Agarwal, A., Bergles, D. E., Kofuji, P., et al. (2016). Glial cell calcium signaling mediates capillary regulation of blood flow in the retina. *J. Neurosci.* 36, 9435–9445. doi: 10.1523/JNEUROSCI.1782-16.2016
- Bohlen, C. J., Bennett, F. C., Tucker, A. F., Collins, H. Y., Mulinyawe, S. B., and Barres, B. A. (2017). Diverse requirements for microglial survival, specification, and function revealed by defined-medium cultures. *Neuron* 94, 759–773.e8. doi: 10.1016/j.neuron.2017.04.043
- Bononi, A., Agnoletto, C., De Marchi, E., Marchi, S., Patergnani, S., Bonora, M., et al. (2011). Protein kinases and phosphatases in the control of cell fate. *Enzyme Res* 2011:329098. doi: 10.4061/2011/329098
- Braunger, B. M., Leimbeck, S. V., Schlecht, A., Volz, C., Jagle, H., and Tamm, E. R. (2015). Deletion of ocular transforming growth factor beta signaling mimics essential characteristics of diabetic retinopathy. *Am. J. Pathol.* 185, 1749–1768. doi: 10.1016/j.ajpath.2015.02.007
- Braunger, B. M., Pielmeier, S., Demmer, C., Landstorfer, V., Kawall, D., Abramov, N., et al. (2013). TGF-beta signaling protects retinal neurons from programmed cell death



- during the development of the mammalian eye. *J. Neurosci.* 33, 14246–14258. doi: 10.1523/JNEUROSCI.0991-13.2013
- Bulavina, L., Szulzewsky, F., Rocha, A., Krabbe, G., Robson, S. C., Matyash, V., et al. (2013). NTPDase1 activity attenuates microglial phagocytosis. *Purinergic Signal* 9, 199–205. doi: 10.1007/s11302-012-9339-y
- Bull, N. D., Limb, G. A., and Martin, K. R. (2008). Human Muller stem cell (MIO-M1) transplantation in a rat model of glaucoma: survival, differentiation, and integration. *Invest. Ophthalmol. Vis. Sci.* 49, 3449–3456. doi: 10.1167/iovs.08-1770
- Busch, S., Kannt, A., Kolibabka, M., Schlotterer, A., Wang, Q., Lin, J., et al. (2014). Systemic treatment with erythropoietin protects the neurovascular unit in a rat model of retinal neurodegeneration. *PLoS One* 9:e102013. doi: 10.1371/journal.pone.0102013
- Cano-Cano, F., Alcalde-Estevéz, E., Gomez-Jaramillo, L., Iturrigui, M., Sanchez-Fernandez, E. M., Garcia Fernandez, J. M., et al. (2021). Anti-inflammatory (M2) response is induced by a sp(2)-Iminosugar glycolipid sulfoxide in diabetic retinopathy. *Front. Immunol.* 12:632132. doi: 10.3389/fimmu.2021.632132
- Cao, J., Ehling, M., Marz, S., Seebach, J., Tarbashevich, K., Sixta, T., et al. (2017). Polarized actin and VE-cadherin dynamics regulate junctional remodelling and cell migration during sprouting angiogenesis. *Nat. Commun.* 8:2210. doi: 10.1038/s41467-017-02373-8
- Carbajo-Lozoya, J., Lutz, S., Feng, Y., Kroll, J., Hammes, H. P., and Wieland, T. (2012). Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium. *Cell. Signal.* 24, 1261–1269. doi: 10.1016/j.cellsig.2012.02.005
- Carey, R. M. (2017). Update on angiotensin AT2 receptors. *Curr. Opin. Nephrol. Hypertens.* 26, 1–96. doi: 10.1097/MNH.0000000000000304
- Caruso, S. M., Ryu, J., Quinn, P. M., and Tsang, S. H. (2020). Precision metabolome reprogramming for imprecision therapeutics in retinitis pigmentosa. *J. Clin. Invest.* 130, 3971–3973. doi: 10.1172/JCI1139239
- Cecchin, D., Sennlaub, F., Levavasseur, E., Leduc, M., and Chemtob, S. (2006). Potential role of microglia in retinal blood vessel formation. *Invest. Ophthalmol. Vis. Sci.* 47, 3595–3602. doi: 10.1167/iovs.05-1522
- Chen, Y., Lin, J., Schlotterer, A., Kurowski, L., Hoffmann, S., Hammad, S., et al. (2021). MicroRNA-124 alleviates retinal vasoregression via regulating Microglial Polarization. *Int. J. Mol. Sci.* 22:11068. doi: 10.3390/ijms222011068
- Chen, D., Peng, C., Ding, X. M., Wu, Y., Zeng, C. J., Xu, L., et al. (2022). Interleukin-4 promotes microglial polarization toward a neuroprotective phenotype after retinal ischemia/reperfusion injury. *Neural Regen. Res.* 17, 2755–2760. doi: 10.4103/1673-5374.339500
- Chen, X., Shao, H., Zhi, Y., Xiao, Q., Su, C., Dong, L., et al. (2016). CD73 pathway contributes to the immunosuppressive ability of mesenchymal stem cells in intraocular autoimmune responses. *Stem Cells Dev.* 25, 337–346. doi: 10.1089/scd.2015.0227
- Claudio, L., Martiny, J. A., and Brosnan, C. F. (1994). Ultrastructural Studies of the Blood-Retina Barrier After Exposure to Interleukin-1 $\beta$  or Tumor Necrosis Factor- $\alpha$ . *Lab Invest.* 70, 850–861.
- Costa-Besada, M. A., Valenzuela, R., Garrido-Gil, P., Villar-Cheda, B., Parga, J. A., Lanciego, J. L., et al. (2018). Paracrine and Intracrine angiotensin 1-7/mas receptor Axis in the substantia nigra of rodents, monkeys, and humans. *Mol. Neurobiol.* 55, 5847–5867. doi: 10.1007/s12035-017-0805-y
- Cramer, T., Gill, R., Thirouin, Z. S., Vaas, M., Sampath, S., Martineau, F., et al. (2022). Cross-talk between GABAergic postsynapse and microglia regulate synapse loss after brain ischemia. *Sci. Adv.* 8:eabj0112. doi: 10.1126/sciadv.abj0112
- Császár, E., Lénárt, N., Cserép, C., Környei, Z., Fekete, R., Pósfai, B., et al. (2021). Microglia control cerebral blood flow and neurovascular coupling via P2Y12R-mediated actions. *bioRxiv*. doi: 10.1101/2021.02.04.429741
- Dang, R., Yang, M., Cui, C., Wang, C., Zhang, W., Geng, C., et al. (2021). Activation of angiotensin-converting enzyme 2/angiotensin (1-7)/mas receptor axis triggers autophagy and suppresses microglia proinflammatory polarization via forkhead box class O1 signaling. *Aging Cell* 20:e113480. doi: 10.1111/acel.13480
- Deliyanti, D., Miller, A. G., Tan, G., Binger, K. J., Samson, A. L., and Wilkinson-Berka, J. L. (2012). Neovascularization is attenuated with aldosterone synthase inhibition in rats with retinopathy. *Hypertension* 59, 607–613. doi: 10.1161/HYPERTENSIONAHA.111.188136
- Deng, Y. Y., Lu, J., Ling, E. A., and Kaur, C. (2009). Monocyte chemoattractant protein-1 (MCP-1) produced via NF-kappaB signaling pathway mediates migration of amoeboid microglia in the periventricular white matter in hypoxic neonatal rats. *Glia* 57, 604–621. doi: 10.1002/glia.20790
- Diaz-Araya, C. M., Provis, J. M., and Penfold, P. L. (1995). Ontogeny and cellular expression of MHC and leucocyte antigens in human retina. *Glia* 15, 458–470. doi: 10.1002/glia.440150409
- Ding, X., Gu, R., Zhang, M., Ren, H., Shu, Q., Xu, G., et al. (2018). Microglia enhanced the angiogenesis, migration and proliferation of co-cultured RMECs. *BMC Ophthalmol.* 18:249. doi: 10.1186/s12886-018-0886-z
- Dudiki, T., Meller, J., Mahajan, G., Liu, H., Zhevlatkova, I., Steff, S., et al. (2020). Microglia control vascular architecture via a TGFbeta1 dependent paracrine mechanism linked to tissue mechanics. *Nat. Commun.* 11:986. doi: 10.1038/s41467-020-14787-y
- Egger, T., Schuligoi, R., Wintersperger, A., Amann, R., Malle, E., and Sattler, W. (2003). Vitamin E (alpha-tocopherol) attenuates cyclo-oxygenase 2 transcription and synthesis in immortalized murine BV-2 microglia. *Biochem. J.* 370, 459–467. doi: 10.1042/BJ20021358
- El-Darzi, N., Mast, N., Buchner, D. A., Saadane, A., Dailey, B., Trichonas, G., et al. (2022). Low-dose anti-HIV drug Efavirenz mitigates retinal vascular lesions in a mouse model of Alzheimer's disease. *Front. Pharmacol.* 13:902254. doi: 10.3389/fphar.2022.902254
- Elmore, M. R., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., et al. (2014). Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. *Neuron* 82, 380–397. doi: 10.1016/j.neuron.2014.02.040
- Enzbrenner, A., Zulliger, R., Biber, J., Pousa, A. M. Q., Schafer, N., Stucki, C., et al. (2021). Sodium iodate-induced degeneration results in local complement changes and inflammatory processes in murine retina. *Int. J. Mol. Sci.* 22:9218. doi: 10.3390/ijms22179218
- Fang, M., Wan, W., Li, Q., Wan, W., Long, Y., Liu, H., et al. (2021). Asiatic acid attenuates diabetic retinopathy through TLR4/MyD88/NF-kappaB p65 mediated modulation of microglia polarization. *Life Sci.* 277:119567. doi: 10.1016/j.lfs.2021.119567
- Farber, K., Markworth, S., Pannasch, U., Nolte, C., Prinz, V., Kronenberg, G., et al. (2008). The ectonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migration. *Glia* 56, 331–341. doi: 10.1002/glia.20606
- Fischer, F., Martin, G., and Agostini, H. T. (2011). Activation of retinal microglia rather than microglial cell density correlates with retinal neovascularization in the mouse model of oxygen-induced retinopathy. *J. Neuroinflammation* 8:120. doi: 10.1186/1742-2094-8-120
- Foulquier, S., Caolo, V., Swennen, G., Milanova, I., Reinhold, S., Recarti, C., et al. (2019). The role of receptor MAS in microglia-driven retinal vascular development. *Angiogenesis* 22, 481–489. doi: 10.1007/s10456-019-09671-3
- Friedrich, U., Datta, S., Schubert, T., Plossl, K., Schneider, M., Grassmann, F., et al. (2015). Synonymous variants in HTRA1 implicated in AMD susceptibility impair its capacity to regulate TGF-beta signaling. *Hum. Mol. Genet.* 24, 6361–6373. doi: 10.1093/hmg/ddv346
- Fritsche, L. G., Chen, W., Schu, M., Yaspan, B. L., Yu, Y., Thorleifsson, G., et al. (2013). Seven new loci associated with age-related macular degeneration. *Nat. Genet.* 45, 433–439. doi: 10.1038/ng.2578
- Fruttiger, M. (2007). Development of the retinal vasculature. *Angiogenesis* 10, 77–88. doi: 10.1007/s10456-007-9065-1
- Fukuda, K., Hirooka, K., Mizote, M., Nakamura, T., Itano, T., and Shiraga, F. (2010). Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor. *Investigat. Ophthalmol. Vis. Sci.* 51, 3629–3638. doi: 10.1167/iovs.09-4107
- Gao, S., Li, N., Wang, Y., Lin, Z., Zhu, Y., Xu, J., et al. (2022). Inhibition of vascular endothelial growth factor alleviates neovascular retinopathy with regulated neurotrophic/proinflammatory cytokines through the modulation of DBI-TSPO signaling. *FASEB J.* 36:e22367. doi: 10.1096/fj.2021011294RRR
- Gao, W., Shen, L., Long, D. D., Pan, T. T., Wang, D., Chai, X. Q., et al. (2022). Angiotensin II type 2 receptor pharmacological agonist, C21, reduces the inflammation and pain hypersensitivity in mice with joint inflammatory pain. *Int. Immunopharmacol.* 110:108921. doi: 10.1016/j.intimp.2022.108921
- Gao, M. L., Zhang, X., Han, F., Xu, J., Yu, S. J., Jin, K., et al. (2022). Functional microglia derived from human pluripotent stem cells empower retinal organ. *Sci. China Life Sci.* 65, 1057–1071. doi: 10.1007/s11427-021-2086-0
- Gariano, R. F., and Gardner, T. W. (2005). Retinal angiogenesis in development and disease. *Nature* 438, 960–966. doi: 10.1038/nature04482
- Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., et al. (2003). VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *J. Cell Biol.* 161, 1163–1177. doi: 10.1083/jcb.200302047
- Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., et al. (2010). Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science* 330, 841–845. doi: 10.1126/science.1194637
- Gosselin, D., Skola, D., Coufal, N. G., Holtman, I. R., Schlachetzki, J. C. M., Sajti, E., et al. (2017). An environment-dependent transcriptional network specifies human microglia identity. *Science* 356:eaal3222. doi: 10.1126/science.aal3222
- Greter, M., Lelios, I., Pelczar, P., Hoefl, G., Price, J., Leboeuf, M., et al. (2012). Stromal-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. *Immunity* 37, 1050–1060. doi: 10.1016/j.immuni.2012.11.001
- Grotegut, P., Perumal, N., Kuehn, S., Smit, A., Dick, H. B., Grus, F. H., et al. (2020). Minocycline reduces inflammatory response and cell death in a S100B retina degeneration model. *J. Neuroinflammation* 17:375. doi: 10.1186/s12974-020-02012-y
- Guimond, M. O., and Gallo-Payet, N. (2012). The angiotensin II type 2 receptor in brain functions: an update. *Int. J. Hypertens.* 2012:351758, 1–18. doi: 10.1155/2012/351758
- Gupta, S., Tiwari, V., Tiwari, P., Parul Mishra, A., Hanif, K., and Shukla, S. (2022). Angiotensin-converting enzyme 2 activation mitigates behavioral deficits and Neuroinflammatory burden in 6-OHDA induced experimental models of Parkinson's disease. *ACS Chem. Neurosci.* 13, 1491–1504. doi: 10.1021/acscchemneuro.1c00797
- Harsing, L. G., Szenasi, G., Zelles, T., and Koles, L. (2021). Purinergic-Glycinergic interaction in neurodegenerative and Neuroinflammatory disorders of the retina. *Int. J. Mol. Sci.* 22:6209. doi: 10.3390/ijms22126209
- Hasegawa, T., McLeod, D. S., Prow, T., Merges, C., Grebe, R., and Luty, G. A. (2008). Vascular precursors in developing human retina. *Invest. Ophthalmol. Vis. Sci.* 49, 2178–2192. doi: 10.1167/iovs.07-0632

- Hatzopoulos, K. M., Vessey, K. A., Wilkinson-Berka, J. L., and Fletcher, E. L. (2014). The vasoneuronal effects of AT1 receptor blockade in a rat model of retinopathy of prematurity. *Invest. Ophthalmol. Vis. Sci.* 55, 3957–3970. doi: 10.1167/iovs.13-13532
- Haupt, F., Krishnasamy, K., Napp, L. C., Augustynik, M., Limbourg, A., Gamrekelashvili, J., et al. (2019). Retinal myeloid cells regulate tip cell selection and vascular branching morphogenesis via notch ligand Delta-like 1. *Sci. Rep.* 9:9798. doi: 10.1038/s41598-019-46308-3
- Hayashi, R., Ishikawa, Y., Sasamoto, Y., Katori, R., Nomura, N., Ichikawa, T., et al. (2016). Co-ordinated ocular development from human iPS cells and recovery of corneal function. *Nature* 531, 376–380. doi: 10.1038/nature17000
- He, D., Xu, H., Zhang, H., Tang, R., Lan, Y., Xing, R., et al. (2022). Disruption of the IL-33-ST2-AKT signaling axis impairs neurodevelopment by inhibiting microglial metabolic adaptation and phagocytic function. *Immunity* 55, 159–173.e9. doi: 10.1016/j.immuni.2021.12.001
- Hickman, S. E., Kingery, N. D., Ohsumi, T. K., Borowsky, M. L., Wang, L. C., Means, T. K., et al. (2013). The microglial sensome revealed by direct RNA sequencing. *Nat. Neurosci.* 16, 1896–1905. doi: 10.1038/nn.3554
- Hu, P., Hunt, N. H., Arfuso, F., Shaw, L. C., Uddin, M. N., Zhu, M., et al. (2017). Increased Indoleamine 2,3-dioxygenase and Quinolinic acid expression in microglia and Muller cells of diabetic human and rodent retina. *Invest. Ophthalmol. Vis. Sci.* 58, 5043–5055. doi: 10.1167/iovs.17-21654
- Hu, P., Thinschmidt, J. S., Caballero, S., Adamson, S., Cole, L., Chan-Ling, T., et al. (2015). Loss of survival factors and activation of inflammatory cascades in brain sympathetic centers in type 1 diabetic mice. *Am. J. Physiol. Endocrinol. Metab.* 308, E688–E698. doi: 10.1152/ajpendo.00504.2014
- Huang, Y., Xu, Z., Xiong, S., Qin, G., Sun, F., Yang, J., et al. (2018a). Dual extra-retinal origins of microglia in the model of retinal microglia repopulation. *Cell Discov* 4:9. doi: 10.1038/s41421-018-0011-8
- Huang, Y., Xu, Z., Xiong, S., Sun, F., Qin, G., Hu, G., et al. (2018b). Repopulated microglia are solely derived from the proliferation of residual microglia after acute depletion. *Nat. Neurosci.* 21, 530–540. doi: 10.1038/s41593-018-0090-8
- Hui, F., Nguyen, C. T., Bedgood, P. A., He, Z., Fish, R. L., Gurrell, R., et al. (2014). Quantitative spatial and temporal analysis of fluorescein angiography dynamics in the eye. *PLoS One* 9:e111330. doi: 10.1371/journal.pone.0111330
- Inada, M., Xu, H., Takeuchi, M., Ito, M., and Chen, M. (2021). Microglia increase tight-junction permeability in coordination with Muller cells under hypoxic condition in an in vitro model of inner blood-retinal barrier. *Exp. Eye Res.* 205:108490. doi: 10.1016/j.exer.2021.108490
- Ingwersen, J., Wingerath, B., Graf, J., Lepka, K., Hofrichter, M., Schroter, F., et al. (2016). Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation. *J. Neuroinflammation* 13:48. doi: 10.1186/s12974-016-0512-z
- Ip, M. S., Domalpally, A., Sun, J. K., and Ehrlich, J. S. (2015). Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. *Ophthalmology* 122, 367–374. doi: 10.1016/j.ophtha.2014.08.048
- Ivanova, E., Alam, N. M., Prusky, G. T., and Sagdullaev, B. T. (2019). Blood-retina barrier failure and vision loss in neuron-specific degeneration. *JCI Insight* 4:e126747. doi: 10.1172/jci.insight.126747
- Jackson, L., Dong, G., Althomali, W., Sayed, M. A., Eldahshan, W., Baban, B., et al. (2020). Delayed Administration of Angiotensin II type 2 receptor (AT2R) agonist compound 21 prevents the development of post-stroke cognitive impairment in diabetes through the modulation of microglia polarization. *Transl. Stroke Res.* 11, 762–775. doi: 10.1007/s12975-019-00752-5
- Jakovljevic, M., Lavrnja, I., Bozic, I., Milosevic, A., Bjelobaba, I., Savic, D., et al. (2019). Induction of NTPDase1/CD39 by reactive microglia and macrophages is associated with the functional state during EAE. *Front. Neurosci.* 13:410. doi: 10.3389/fnins.2019.00410
- Javelaud, D., and Mauviel, A. (2004). Mammalian transforming growth factor- $\beta$ s: Smad signaling and physio-pathological roles. *Int. J. Biochem. Cell Biol.* 36, 1161–1165. doi: 10.1016/s1357-2725(03)00255-3
- Jeon, S. J., Huh, J., Jeong, E., Park, C. K., and Park, H. Y. L. (2022). Angiotensin II related glial cell activation and necroptosis of retinal ganglion cells after systemic hypotension in glaucoma. *Cell Death Dis.* 13:323. doi: 10.1038/s41419-022-04762-4
- Jiang, T., Gao, L., Lu, J., and Zhang, Y. D. (2013). ACE2-Ang-(1-7)-mas Axis in brain: a potential target for prevention and treatment of ischemic stroke. *Curr. Neuropharmacol.* 11, 209–217. doi: 10.2174/1570159X11311020007
- Jin, N., Gao, L., Fan, X., and Xu, H. (2017). Friend or foe? Resident microglia vs bone marrow-derived microglia and their roles in the retinal degeneration. *Mol. Neurobiol.* 54, 4094–4112. doi: 10.1007/s12035-016-9960-9
- Jo, D. H., Yun, J. H., Cho, C. S., Kim, J. H., Kim, J. H., and Cho, C. H. (2019). Interaction between microglia and retinal pigment epithelial cells determines the integrity of outer blood-retinal barrier in diabetic retinopathy. *Glia* 67, 321–331. doi: 10.1002/glia.23542
- Jolivel, V., Bicker, F., Biname, F., Ploen, R., Keller, S., Gollan, R., et al. (2015). Perivascular microglia promote blood vessel disintegration in the ischemic penumbra. *Acta Neuropathol.* 129, 279–295. doi: 10.1007/s00401-014-1372-1
- Jorstad, N. L., Wilken, M. S., Grimes, W. N., Wohl, S. G., VandenBosch, L. S., Yoshimatsu, T., et al. (2017). Stimulation of functional neuronal regeneration from Muller glia in adult mice. *Nature* 548, 103–107. doi: 10.1038/nature23283
- Jovanovic, J., Liu, X., Kokona, D., Zinkernagel, M. S., and Ebnetter, A. (2020). Inhibition of inflammatory cells delays retinal degeneration in experimental retinal vein occlusion in mice. *Glia* 68, 574–588. doi: 10.1002/glia.23739
- Kigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., and Popovich, P. G. (2009). Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. *J. Neurosci.* 29, 13435–13444. doi: 10.1523/JNEUROSCI.3257-09.2009
- Kim, W. K., Hwang, S. Y., Oh, E. S., Piao, H. Z., Kim, K. W., and Han, I. O. (2004). TGF- $\beta$ 1 represses activation and resultant death of microglia via inhibition of phosphatidylinositol 3-kinase activity. *J. Immunol.* 172, 7015–7023. doi: 10.4049/jimmunol.172.11.7015
- Kokona, D., Ebnetter, A., Escher, P., and Zinkernagel, M. S. (2018). Colony-stimulating factor 1 receptor inhibition prevents disruption of the blood-retina barrier during chronic inflammation. *J. Neuroinflammation* 15:340. doi: 10.1186/s12974-018-1373-4
- Kooragayala, K., Gotoh, N., Cogliati, T., Nellissery, J., Kaden, T. R., French, S., et al. (2015). Quantification of oxygen consumption in retina ex vivo demonstrates limited reserve capacity of photoreceptor mitochondria. *Invest. Ophthalmol. Vis. Sci.* 56, 8428–8436. doi: 10.1167/iovs.15-17901
- Krady, J. K., Basu, A., Allen, C. M., Xu, Y., LaNoue, K. F., Gardner, T. W., et al. (2005). Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. *Diabetes* 54, 1559–1565. doi: 10.2337/diabetes.54.5.1559
- Kubota, Y., Takubo, K., Shimizu, T., Ohno, H., Kishi, K., Shibuya, M., et al. (2009). M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. *J. Exp. Med.* 206, 1089–1102. doi: 10.1084/jem.20081605
- Kurihara, T., Ozawa, Y., Shinoda, K., Nagai, N., Inoue, M., Oike, Y., et al. (2006). Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. *Invest. Ophthalmol. Vis. Sci.* 47, 5545–5552. doi: 10.1167/iovs.06-0478
- Lan, X., Han, X., Li, Q., Yang, Q. W., and Wang, J. (2017). Modulators of microglial activation and polarization after intracerebral haemorrhage. *Nat. Rev. Neurol.* 13, 420–433. doi: 10.1038/nrneurol.2017.69
- Lee, J. E., Liang, K. J., Fariss, R. N., and Wong, W. T. (2008). Ex vivo dynamic imaging of retinal microglia using time-lapse confocal microscopy. *Invest. Ophthalmol. Vis. Sci.* 49, 4169–4176. doi: 10.1167/iovs.08-2076
- Li, Y., Liu, D. X., Li, M. Y., Qin, X. X., Fang, W. G., Zhao, W. D., et al. (2014). Ephrin-A3 and ephrin-A4 contribute to microglia-induced angiogenesis in brain endothelial cells. *Anat Rec (Hoboken)* 297, 1908–1918. doi: 10.1002/ar.22998
- Li, J., Yu, S., Lu, X., Cui, K., Tang, X., Xu, Y., et al. (2021). The phase changes of M1/M2 phenotype of microglia/macrophage following oxygen-induced retinopathy in mice. *Inflamm. Res.* 70, 183–192. doi: 10.1007/s00011-020-01427-w
- Lim, H. M., Heo, W., Han, J. W., Lee, M. G., and Kim, J. Y. (2018). NPP1 is responsible for potent extracellular ATP hydrolysis as NTPDase1 in primary cultured murine microglia. *Purinergic Signal* 14, 157–166. doi: 10.1007/s11302-018-9601-z
- Lim, L. S., Ling, L. H., Ong, P. G., Foulds, W., Tai, E. S., Wong, E., et al. (2014). Dynamic responses in retinal vessel caliber with flicker light stimulation in eyes with diabetic retinopathy. *Invest. Ophthalmol. Vis. Sci.* 55, 5207–5213. doi: 10.1167/iovs.14-14301
- Liu, Y. P., Kuznetsova, T., Thijs, L., Jin, Y., Schmitz, B., Brand, S. M., et al. (2011). Are retinal microvascular phenotypes associated with the 1675G/a polymorphism in the angiotensin II type-2 receptor gene? *Am. J. Hypertens.* 24, 1300–1305. doi: 10.1038/ajh.2011.151
- Liu, M., Shi, P., and Summers, C. (2016). Direct anti-inflammatory effects of angiotensin-(1-7) on microglia. *J. Neurochem.* 136, 163–171. doi: 10.1111/jnc.13386
- Liu, Z., Shi, H., Xu, J., Yang, Q., Ma, Q., Mao, X., et al. (2022). Single-cell transcriptome analyses reveal microglia types associated with proliferative retinopathy. *JCI Insight* 7:e160940. doi: 10.1172/jci.insight.160940
- Liu, J., Tsang, J. K. W., Fung, F. K. C., Chung, S. K., Fu, Z., and Lo, A. C. Y. (2022). Retinal microglia protect against vascular damage in a mouse model of retinopathy of prematurity. *Front. Pharmacol.* 13:945130. doi: 10.3389/fphar.2022.945130
- Losenkova, K., Takeda, A., Ragauskas, S., Cerrada-Gimenez, M., Vahatupa, M., Kaja, S., et al. (2022). CD73 controls ocular adenosine levels and protects retina from light-induced phototoxicity. *Cell. Mol. Life Sci.* 79:152. doi: 10.1007/s00018-022-04187-4
- Lu, W., Hu, H., Sevigny, J., Gabelt, B. T., Kaufman, P. L., Johnson, E. C., et al. (2015). Rat, mouse, and primate models of chronic glaucoma show sustained elevation of extracellular ATP and altered purinergic signaling in the posterior eye. *Invest. Ophthalmol. Vis. Sci.* 56, 3075–3083. doi: 10.1167/iovs.14-15891
- Lutty, G. A., and McLeod, D. S. (2018). Development of the hyaloid, choroidal and retinal vasculatures in the fetal human eye. *Prog. Retin. Eye Res.* 62, 58–76. doi: 10.1016/j.pretyres.2017.10.001
- Ma, W., Silverman, S. M., Zhao, L., Villasmil, R., Campos, M. M., Amaral, J., et al. (2019). Absence of TGF $\beta$  signaling in retinal microglia induces retinal degeneration and exacerbates choroidal neovascularization. *elife* 8:e42049. doi: 10.7554/eLife.42049
- Maning, J., Negussie, S., Clark, M. A., and Lympelopoulou, A. (2017). Biased agonism/antagonism at the AngII-AT1 receptor: implications for adrenal aldosterone production and cardiovascular therapy. *Pharmacol. Res.* 125, 14–20. doi: 10.1016/j.phrs.2017.05.009

- Matyash, M., Zabiagalov, O., Wendt, S., Matyash, V., and Kettenmann, H. (2017). The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain. *PLoS One* 12:e0175012. doi: 10.1371/journal.pone.0175012
- McCarthy, C. A., Vinh, A., Broughton, B. R., Sobey, C. G., Callaway, J. K., and Widdop, R. E. (2012). Angiotensin II type 2 receptor stimulation initiated after stroke causes neuroprotection in conscious rats. *Hypertension* 60, 1531–1537. doi: 10.1161/HYPERTENSIONAHA.112.199646
- McCarthy, C. A., Vinh, A., Miller, A. A., Hallberg, A., Alterman, M., Callaway, J. K., et al. (2014). Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats. *PLoS One* 9:e95762. doi: 10.1371/journal.pone.0095762
- McPherson, S. W., Heuss, N. D., Lehmann, U., Roehrich, H., Abedin, M., and Gregerson, D. S. (2019). The retinal environment induces microglia-like properties in recruited myeloid cells. *J. Neuroinflammation* 16:151. doi: 10.1186/s12974-019-1546-9
- McVicar, C. M., Hamilton, R., Colhoun, L. M., Gardiner, T. A., Brines, M., Cerami, A., et al. (2011). Intervention with an erythropoietin-derived peptide protects against neurological and vascular degeneration during diabetic retinopathy. *Diabetes* 60, 2995–3005. doi: 10.2337/db11-0026
- Mehrabadi, A. R., Korolainen, M. A., Odero, G., Miller, D. W., and Kauppinen, T. M. (2017). Poly(ADP-ribose) polymerase-1 regulates microglia mediated decrease of endothelial tight junction integrity. *Neurochem. Int.* 108, 266–271. doi: 10.1016/j.neuint.2017.04.014
- Menon, M., Mohammadi, S., Davila-Velderrain, J., Goods, B. A., Cadwell, T. D., Xing, Y., et al. (2019). Single-cell transcriptomic atlas of the human retina identifies cell types associated with age-related macular degeneration. *Nat. Commun.* 10:4902. doi: 10.1038/s41467-019-12780-8
- Micklisch, S., Lin, Y., Jacob, S., Karlstetter, M., Dannhausen, K., Dasari, P., et al. (2017). Age-related macular degeneration associated polymorphism rs10490924 in ARMS2 results in deficiency of a complement activator. *J. Neuroinflammation* 14:4. doi: 10.1186/s12974-016-0776-3
- Mills, S. A., Jobling, A. I., Dixon, M. A., Bui, B. V., Vessey, K. A., Phipps, J. A., et al. (2021). Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic retinopathy. *Proc. Natl. Acad. Sci. U. S. A.* 118:e2112561118. doi: 10.1073/pnas.2112561118
- Misra Tadesse, Y. Y., Yossuck, P., and Higgins, R. D. (2001). Captopril improves retinal neovascularization via endothelin-1. *Invest. Ophthalmol. Vis. Sci.* 42, 1867–1872.
- Moravski, C. J., Kelly, D. J., Cooper, M. E., Gilbert, R. E., Bertram, J. F., Shahinfar, S., et al. (2000). Retinal neovascularization is prevented by blockade of the renin-angiotensin system. *Hypertension* 36, 1099–1104. doi: 10.1161/01.hyp.36.6.1099
- Muffat, J., Li, Y., Yuan, B., Mitalipova, M., Omer, A., Corcoran, S., et al. (2016). Efficient derivation of microglia-like cells from human pluripotent stem cells. *Nat. Med.* 22, 1358–1367. doi: 10.1038/nm.4189
- Muliyil, S., Levett, C., Dusterhoff, S., Dulloo, I., Cowley, S. A., and Freeman, M. (2020). ADAM17-triggered TNF signalling protects the ageing Drosophila retina from lipid droplet-mediated degeneration. *EMBO J.* 39:e104415. doi: 10.15252/embj.2020104415
- Muthusamy, A., Lin, C.-M., Shanmugam, S., Lindner, H. M., Abcouwer, S. F., and Antonetti, D. A. (2014). Ischemia-reperfusion injury induces Occludin phosphorylation/ubiquitination and retinal vascular permeability in a VEGFR-2-dependent manner. *J. Cereb. Blood Flow Metab.* 34, 522–531. doi: 10.1038/jcbfm.2013.230
- O'Leary, F., and Campbell, M. (2021). The blood-retina barrier in health and disease. *FEBS J.* doi: 10.1111/febs.16330
- Osborne, N. N., Casson, R. J., Wood, J. P., Chidlow, G., Graham, M., and Melena, J. (2004). Retinal ischemia: mechanisms of damage and potential therapeutic strategies. *Prog. Retin. Eye Res.* 23, 91–147. doi: 10.1016/j.preteyeres.2003.12.001
- Oshima, M., Oshima, H., and Taketo, M. M. (1996). TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. *Dev. Biol.* 179, 297–302. doi: 10.1006/dbio.1996.0259
- Oultz, H. H., Tattersall, I. W., Kofler, N. M., Steinbach, N., and Kitajewski, J. (2011). Notch1 controls macrophage recruitment and notch signaling is activated at sites of endothelial cell anastomosis during retinal angiogenesis in mice. *Blood* 118, 3436–3439. doi: 10.1182/blood-2010-12-327015
- Ozaki, E., Delaney, C., Campbell, M., and Doyle, S. L. (2022). Minocycline suppresses disease-associated microglia (DAM) in a model of photoreceptor cell degeneration. *Exp. Eye Res.* 217:108953. doi: 10.1016/j.exer.2022.108953
- Parkhurst, C. N., Yang, G., Ninan, I., Savas, J. N., Yates, J. R. 3rd, Lafaille, J. J., et al. (2013). Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. *Cells* 155, 1596–1609. doi: 10.1016/j.cell.2013.11.030
- Phipps, J. A., Vessey, K. A., Brandli, A., Nag, N., Tran, M. X., Jobling, A. I., et al. (2018). The role of angiotensin II/AT1 receptor signaling in regulating retinal microglial activation. *Invest. Ophthalmol. Vis. Sci.* 59, 487–498. doi: 10.1167/iovs.17-22416
- Prinz, M., Masuda, T., Wheeler, M. A., and Quintana, F. J. (2021). Microglia and central nervous system-associated macrophages-from origin to disease modulation. *Annu. Rev. Immunol.* 39, 251–277. doi: 10.1146/annurev-immunol-093019-110159
- Puthenparampil, M., Torresin, T., Franciotta, S., Marin, A., De Napoli, F., Mauceri, V. A., et al. (2022). Hyper-reflecting foci in multiple sclerosis retina associate with macrophage/microglia-derived cytokines in cerebrospinal fluid. *Front. Immunol.* 13:852183. doi: 10.3389/fimmu.2022.852183
- Rana, I., Suphaimol, V., Jerome, J. R., Talia, D. M., Deliyanti, D., and Wilkinson-Berka, J. L. (2020). Angiotensin II and aldosterone activate retinal microglia. *Exp. Eye Res.* 191:107902. doi: 10.1016/j.exer.2019.107902
- Rebello, A. P., Eidhof, I., Cintra, V. P., Guillot-Noel, L., Pereira, C. V., Timmann, D., et al. (2021). Biallelic loss-of-function variations in PRDX3 cause cerebellar ataxia. *Brain* 144, 1467–1481. doi: 10.1093/brain/awab071
- Regenhardt, R. W., Mecca, A. P., Desland, F., Ritucci-Chinni, P. F., Ludin, J. A., Greenstein, D., et al. (2014). Centrally administered angiotensin-(1-7) increases the survival of stroke-prone spontaneously hypertensive rats. *Exp. Physiol.* 99, 442–453. doi: 10.1113/expphysiol.2013.075242
- Ritter, M. R., Banin, E., Moreno, S. K., Aguilar, E., Dorrell, M. I., and Friedlander, M. (2006). Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. *J. Clin. Invest.* 116, 3266–3276. doi: 10.1172/JCI29683
- Rivas-Santisteban, R., Lillo, J., Munoz, A., Rodriguez-Perez, A. I., Labandeira-Garcia, J. L., Navarro, G., et al. (2021). Novel interactions involving the mas receptor show potential of the renin-angiotensin system in the regulation of microglia activation: altered expression in parkinsonism and dyskinesia. *Neurotherapeutics* 18, 998–1016. doi: 10.1007/s13311-020-00986-4
- Roche, S. L., Ruiz-Lopez, A. M., Moloney, J. N., Byrne, A. M., and Cotter, T. G. (2018). Microglial-induced Muller cell gliosis is attenuated by progesterone in a mouse model of retinitis pigmentosa. *Glia* 66, 295–310. doi: 10.1002/glia.22763
- Roche, S. L., Wyse-Jackson, A. C., Ruiz-Lopez, A. M., Byrne, A. M., and Cotter, T. G. (2017). Fractalkine-CX3CR1 signaling is critical for progesterone-mediated neuroprotection in the retina. *Sci. Rep.* 7:43067. doi: 10.1038/srep43067
- Rodrigues-Neves, A. C., Aires, I. D., Vindeirinho, J., Boia, R., Madeira, M. H., Goncalves, F. Q., et al. (2018). Elevated pressure changes the purinergic system of microglial cells. *Front. Pharmacol.* 9:16. doi: 10.3389/fphar.2018.00016
- Rodriguez-Perez, A. I., Borrajo, A., Rodriguez-Pallares, J., Guerra, M. J., and Labandeira-Garcia, J. L. (2015). Interaction between NADPH-oxidase and rho-kinase in angiotensin II-induced microglial activation. *Glia* 63, 466–482. doi: 10.1002/glia.22765
- Rymo, S. F., Gerhardt, H., Wolfhagen Sand, F., Lang, R., Uv, A., and Betsholtz, C. (2011). A two-way communication between microglial cells and angiogenic sprouts regulates angiogenesis in aortic ring cultures. *PLoS One* 6:e15846. doi: 10.1371/journal.pone.0015846
- Samardzija, M., Caprara, C., Heynen, S. R., Willcox DeParis, S., Meneau, I., Traber, G., et al. (2014). A mouse model for studying cone photoreceptor pathologies. *Invest. Ophthalmol. Vis. Sci.* 55, 5304–5313. doi: 10.1167/iovs.14-14789
- Santos, A. M., Calvente, R., Tassi, M., Carrasco, M. C., Martin-Oliva, D., Marin-Teva, J. L., et al. (2008). Embryonic and postnatal development of microglial cells in the mouse retina. *J. Comp. Neurol.* 506, 224–239. doi: 10.1002/cne.21538
- Sarlos, S., and Wilkinson-Berka, J. L. (2005). The renin-angiotensin system and the developing retinal vasculature. *Investigat. Ophthalmol. Vis. Sci.* 46:1069. doi: 10.1167/iovs.04-0885
- Sasahara, M., Otani, A., Oishi, A., Kojima, H., Yodoi, Y., Kameda, T., et al. (2008). Activation of bone marrow-derived microglia promotes photoreceptor survival in inherited retinal degeneration. *Am. J. Pathol.* 172, 1693–1703. doi: 10.2353/ajpath.2008.080024
- Scholz, R., Sobotka, M., Caramoy, A., Stempf, T., Moehle, C., and Langmann, T. (2015). Minocycline counter-regulates pro-inflammatory microglia responses in the retina and protects from degeneration. *J. Neuroinflammation* 12:209. doi: 10.1186/s12974-015-0431-4
- Shen, W., Chung, S. H., Irhimeh, M. R., Li, S., Lee, S. R., and Gillies, M. C. (2014). Systemic administration of erythropoietin inhibits retinopathy in RCS rats. *PLoS One* 9:e104759. doi: 10.1371/journal.pone.0104759
- Sherr, C. J., Rettenmier, C. W., Sacca, R., Roussel, M. F., Look, A. T., and Stanley, E. R. (1985). The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF 1. *Cells* 41, 665–676. doi: 10.1016/s0092-8674(85)80047-7
- Shi, P., Diez-Freire, C., Jun, J. Y., Qi, Y., Katovich, M. J., Li, Q., et al. (2010). Brain microglial cytokines in neurogenic hypertension. *Hypertension* 56, 297–303. doi: 10.1161/HYPERTENSIONAHA.110.150409
- Shiraki, N., Maruyama, K., Hayashi, R., Oguchi, A., Murakawa, Y., Katayama, T., et al. (2022). PAX6-positive microglia evolve locally in hiPSC-derived ocular organoids. *Stem Cell Reports* 17, 221–230. doi: 10.1016/j.stemcr.2021.12.009
- Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., et al. (1992). Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. *Nature* 359, 693–699. doi: 10.1038/359693a0
- Siddiqui, T. A., Lively, S., and Schlichter, L. C. (2016). Complex molecular and functional outcomes of single versus sequential cytokine stimulation of rat microglia. *J. Neuroinflammation* 13:66. doi: 10.1186/s12974-016-0531-9
- Singhal, S., Lawrence, J. M., Bhatia, B., Ellis, J. S., Kwan, A. S., Macneil, A., et al. (2008). Chondroitin sulfate proteoglycans and microglia prevent migration and integration of grafted Muller stem cells into degenerating retina. *Stem Cells* 26, 1074–1082. doi: 10.1634/stemcells.2007-0898
- Spaide, R. F. (2013). Clinical manifestations of choroidal neovascularization in AMD. *Age Relat. Macular Degener.* Berlin, Heidelberg: Springer. 111–119. doi: 10.1007/978-3-642-22107-1\_7
- Stahl, A., Connor, K. M., Sapieha, P., Chen, J., Dennison, R. J., Krah, N. M., et al. (2010). The mouse retina as an angiogenesis model. *Invest. Ophthalmol. Vis. Sci.* 51, 2813–2826. doi: 10.1167/iovs.10-5176

- Stanley, E. R., and Chitu, V. (2014). CSF-1 receptor signaling in myeloid cells. *Cold Spring Harb. Perspect. Biol.* 6. doi: 10.1101/cshperspect.a021857
- Sterling, J. K., Baumann, B., Foshe, S., Voigt, A., Guttha, S., Alnemri, A., et al. (2022). Inflammatory adipose activates a nutritional immunity pathway leading to retinal dysfunction. *Cell Rep.* 39:110942. doi: 10.1016/j.celrep.2022.110942
- Sumners, C., Alleyne, A., Rodriguez, V., Pioquinto, D. J., Ludin, J. A., Kar, S., et al. (2020). Brain angiotensin type-1 and type-2 receptors: cellular locations under normal and hypertensive conditions. *Hypertens. Res.* 43, 281–295. doi: 10.1038/s41440-019-0374-8
- Sun, L., Wang, R., Hu, G., Liu, H., Lv, K., Duan, Y., et al. (2021). Single cell RNA sequencing (scRNA-Seq) deciphering pathological alterations in streptozotocin-induced diabetic retinas. *Exp. Eye Res.* 210:108718. doi: 10.1016/j.exer.2021.108718
- Takahashi, K., Rochford, C. D., and Neumann, H. (2005). Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. *J. Exp. Med.* 201, 647–657. doi: 10.1084/jem.20041611
- Takeda, A., Shinozaki, Y., Kashiwagi, K., Ohno, N., Eto, K., Wake, H., et al. (2018). Microglia mediate non-cell-autonomous cell death of retinal ganglion cells. *Glia* 66, 2366–2384. doi: 10.1002/glia.23475
- Tang, X., Cui, K., Lu, X., Wu, P., Yu, S., Yang, B., et al. (2022). A novel hypoxia-inducible factor 1alpha inhibitor KC7F2 attenuates oxygen-dependent retinal neovascularization. *Invest. Ophthalmol. Vis. Sci.* 63:13. doi: 10.1167/iov.63.6.13
- Tang, Y., and Le, W. (2016). Differential roles of M1 and M2 microglia in neurodegenerative diseases. *Mol. Neurobiol.* 53, 1181–1194. doi: 10.1007/s12035-014-9070-5
- Tang, L., Zhang, C., Lu, L., Tian, H., Liu, K., Luo, D., et al. (2022). Melatonin maintains inner blood-retinal barrier by regulating microglia via inhibition of PI3K/Akt/Stat3/NF-kappaB signaling pathways in experimental diabetic retinopathy. *Front. Immunol.* 13:831660. doi: 10.3389/fimmu.2022.831660
- Tao, L., Qiu, Y., Fu, X., Lin, R., Lei, C., Wang, J., et al. (2016). Angiotensin-converting enzyme 2 activator diminazene aceturate prevents lipopolysaccharide-induced inflammation by inhibiting MAPK and NF-kappaB pathways in human retinal pigment epithelium. *J. Neuroinflammation* 13:35. doi: 10.1186/s12974-016-0489-7
- Tay, T. L., Mai, D., Dautzenberg, J., Fernandez-Klett, F., Lin, G. S., Datta, M., et al. (2017). A new fate mapping system reveals context-dependent random or clonal expansion of microglia. *Nat. Neurosci.* 20, 793–803. doi: 10.1038/nn.4547
- Taylor, R. A., Chang, C. F., Goods, B. A., Hammond, M. D., Mac Grory, B., Ai, Y., et al. (2017). TGF-beta1 modulates microglial phenotype and promotes recovery after intracerebral hemorrhage. *J. Clin. Invest.* 127, 280–292. doi: 10.1172/JCI88647
- Ting, K. K., Zhao, Y., Shen, W., Coleman, P., Yam, M., Chan-Ling, T., et al. (2019). Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models. *Diabetologia* 62, 322–334. doi: 10.1007/s00125-018-4770-4
- Todd, L., Palazzo, I., Suarez, L., Liu, X., Volkov, L., Hoang, T. V., et al. (2019). Reactive microglia and IL1beta/IL-1R1-signaling mediate neuroprotection in excitotoxin-damaged mouse retina. *J. Neuroinflammation* 16:118. doi: 10.1186/s12974-019-1505-5
- Toonen, J. A., Solga, A. C., Ma, Y., and Gutmann, D. H. (2017). Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology. *J. Exp. Med.* 214, 17–25. doi: 10.1084/jem.20160447
- Tosi, G. M., Neri, G., Caldi, E., Fusco, F., Bacci, T., Tarantello, A., et al. (2018). TGF-beta concentrations and activity are down-regulated in the aqueous humor of patients with neovascular age-related macular degeneration. *Sci. Rep.* 8:8053. doi: 10.1038/s41598-018-26442-0
- Tuhina Prasad, A. V., and Li, Q. (2014). Expression and cellular localization of the mas receptor in the adult and developing mouse retina. *Mol. Vis.* 20:1443.
- Usui-Ouchi, A., Eade, K., Giles, S., Ideguchi, Y., Ouchi, Y., Aguilar, E., et al. (2022). Deletion of Tgfbeta signal in activated microglia prolongs hypoxia-induced retinal neovascularization enhancing Igf1 expression and retinal leukostasis. *Glia* 70, 1762–1776. doi: 10.1002/glia.24218
- Usui-Ouchi, A., and Friedlander, M. (2019). Anti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily better. *J. Clin. Invest.* 129, 3032–3034. doi: 10.1172/JCI129862
- Usui-Ouchi, A., Usui, Y., Kurihara, T., Aguilar, E., Dorrell, M. I., Ideguchi, Y., et al. (2020). Retinal microglia are critical for subretinal neovascular formation. *JCI Insight* 5:e137317. doi: 10.1172/jci.insight.137317
- Verma, A., Zhu, P., de Kloet, A., Krause, E., Sumners, C., and Li, Q. (2019). Angiotensin receptor expression revealed by reporter mice and beneficial effects of AT2R agonist in retinal cells. *Exp. Eye Res.* 187:107770. doi: 10.1016/j.exer.2019.107770
- Villacampa, N., Almolda, B., Vilella, A., Campbell, I. L., Gonzalez, B., and Castellano, B. (2015). Astrocyte-targeted production of IL-10 induces changes in microglial reactivity and reduces motor neuron death after facial nerve axotomy. *Glia* 63, 1166–1184. doi: 10.1002/glia.22807
- Vincent, J. A., and Mohr, S. (2007). Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. *Diabetes* 56, 224–230. doi: 10.2337/db06-0427
- Waanders, F., de Vries, L. V., van Goor, H., Hillebrands, J. L., Laverman, G. D., Bakker, S. J., et al. (2011). Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage. *Curr. Vasc. Pharmacol.* 9, 594–605. doi: 10.2174/157016111796642689
- Wagner, J., Jan Danser, A. H., Derkx, F. H., de Jong, T. V., Paul, M., Mullins, J. J., et al. (1996). Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. *Br. J. Ophthalmol.* 80, 159–163. doi: 10.1136/bjo.80.2.159
- Walker, D. G., and Lue, L. F. (2015). Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. *Alzheimers Res. Ther.* 7:56. doi: 10.1186/s13195-015-0139-9
- Walshe, T. E., Saint-Geniez, M., Maharaj, A. S., Sekiyama, E., Maldonado, A. E., and D'Amore, P. A. (2009). TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. *PLoS One* 4:e5149. doi: 10.1371/journal.pone.0005149
- Wan, P., Su, W., Zhang, Y., Li, Z., Deng, C., Li, J., et al. (2020). LncRNA H19 initiates microglial pyroptosis and neuronal death in retinal ischemia/reperfusion injury. *Cell Death Differ.* 27, 176–191. doi: 10.1038/s41418-019-0351-4
- Wang, L. L., Chen, H., Huang, K., and Zheng, L. (2012). Elevated histone acetylations in Muller cells contribute to inflammation: a novel inhibitory effect of minocycline. *Glia* 60, 1896–1905. doi: 10.1002/glia.22405
- Wang, Y., Chen, S., Wang, J., Liu, Y., Chen, Y., Wen, T., et al. (2021). MicroRNA-93/STAT3 signalling pathway mediates retinal microglia activation and protects retinal ganglion cells in an acute ocular hypertension model. *Cell Death Dis.* 12:41. doi: 10.1038/s41419-020-03337-5
- Wang, G., Li, X., Li, N., Wang, X., He, S., Li, W., et al. (2022). Icarin alleviates uveitis by targeting peroxiredoxin 3 to modulate retinal microglia M1/M2 phenotypic polarization. *Redox Biol.* 52:102297. doi: 10.1016/j.redox.2022.102297
- Wang, K., Peng, B., and Lin, B. (2014). Fractalkine receptor regulates microglial neurotoxicity in an experimental mouse glaucoma model. *Glia* 62, 1943–1954. doi: 10.1002/glia.22715
- Wang, M., Wang, X., Zhao, L., Ma, W., Rodriguez, I. R., Fariss, R. N., et al. (2014). Macrogliamicroglia interactions via TSPO signaling regulates microglial activation in the mouse retina. *J. Neurosci.* 34, 3793–3806. doi: 10.1523/JNEUROSCI.3153-13.2014
- Wang, S. K., Xue, Y., and Cepko, C. L. (2020). Microglia modulation by TGF-beta1 protects cones in mouse models of retinal degeneration. *J. Clin. Invest.* 130, 4360–4369. doi: 10.1172/JCI136160
- Wei, S., Nandi, S., Chitu, V., Yeung, Y. G., Yu, W., Huang, M., et al. (2010). Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. *J. Leukoc. Biol.* 88, 495–505. doi: 10.1189/jlb.1209822
- Wieghofer, P., Hagemeyer, N., Sankowski, R., Schlecht, A., Staszewski, O., Amann, L., et al. (2021). Mapping the origin and fate of myeloid cells in distinct compartments of the eye by single-cell profiling. *EMBO J.* 40:e105123. doi: 10.15252/embj.2020105123
- Wu, J., Gao, G., Shi, F., Xie, H., Yang, Q., Liu, D., et al. (2021). Activated microglia-induced neuroinflammatory cytokines lead to photoreceptor apoptosis in Abeta-injected mice. *J. Mol. Med. (Berl)* 99, 713–728. doi: 10.1007/s00109-021-02046-6
- Wurm, A., Iandiev, I., Hollborn, M., Wiedemann, P., Reichenbach, A., Zimmermann, H., et al. (2008). Purinergic receptor activation inhibits osmotic glial cell swelling in the diabetic rat retina. *Exp. Eye Res.* 87, 385–393. doi: 10.1016/j.exer.2008.07.004
- Xie, H., Zhang, C., Liu, D., Yang, Q., Tang, L., Wang, T., et al. (2021). Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy. *Diabetologia* 64, 211–225. doi: 10.1007/s00125-020-05299-x
- Xin, H., Zhou, F., Liu, T., Li, G. Y., Liu, J., Gao, Z. Z., et al. (2012). Icarin ameliorates streptozotocin-induced diabetic retinopathy in vitro and in vivo. *Int. J. Mol. Sci.* 13, 866–878. doi: 10.3390/ijms13010866
- Xu, H., Chen, M., Manivannan, A., Lois, N., and Forrester, J. V. (2008). Age-dependent accumulation of lipofuscin in perivascular and subretinal microglia in experimental mice. *Aging Cell* 7, 58–68. doi: 10.1111/j.1474-9726.2007.00351.x
- Xu, Y., Cui, K., Li, J., Tang, X., Lin, J., Lu, X., et al. (2020). Melatonin attenuates choroidal neovascularization by regulating macrophage/microglia polarization via inhibition of RhoA/ROCK signaling pathway. *J. Pineal Res.* 69:e12660. doi: 10.1111/jpi.12660
- Xu, Y., Lu, X., Hu, Y., Yang, B., Tsui, C. K., Yu, S., et al. (2018). Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1alpha-VEGF pathway in oxygen-induced retinopathy mice. *J. Pineal Res.* 64:e12473. doi: 10.1111/jpi.12473
- Xu, X.-J., Wang, S.-M., Jin, Y., Hu, Y.-T., Feng, K., and Ma, Z.-Z. (2017). Melatonin delays photoreceptor degeneration in a mouse model of autosomal recessive retinitis pigmentosa. *J. Pineal Res.* 63. doi: 10.1111/jpi.12428
- Yan, L., Lee, S., Lazzaro, D. R., Aranda, J., Grant, M. B., and Chaqour, B. (2015). Single and compound Knock-outs of MicroRNA (miRNA)-155 and its Angiogenic gene target CCN1 in mice Alter vascular and Neovascular growth in the retina via resident microglia. *J. Biol. Chem.* 290, 23264–23281. doi: 10.1074/jbc.M115.646950
- Yang, P., Chen, L., Shi, Y., Zhou, F., Tian, H., Li, J., et al. (2021). Progesterone alters the activation and typing of the microglia in the optic nerve crush model. *Exp. Eye Res.* 212:108805. doi: 10.1016/j.exer.2021.108805
- Yang, X., Zhao, L., Campos, M. M., Abu-Asab, M., Ortolan, D., Hotaling, N., et al. (2020). CSF1R blockade induces macrophage ablation and results in mouse choroidal vascular atrophy and RPE disorganization. *elife* 9:e55564. doi: 10.7554/eLife.55564
- Ye, D., Xu, Y., Shi, Y., Fan, M., Lu, P., Bai, X., et al. (2022). Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model. *J. Pineal Res.* 73:e12828. doi: 10.1111/jpi.12828

- Yoon, H. E., Kim, E. N., Kim, M. Y., Lim, J. H., Jang, I. A., Ban, T. H., et al. (2016). Age-associated changes in the vascular renin-angiotensin system in mice. *Oxidative Med. Cell. Longev.* 2016, 1–14. doi: 10.1155/2016/6731093
- Yu, W., Chen, J., Xiong, Y., Pixley, F. J., Dai, X. M., Yeung, Y. G., et al. (2008). CSF-1 receptor structure/function in *MacCsf1r*<sup>-/-</sup> macrophages: regulation of proliferation, differentiation, and morphology. *J. Leukoc. Biol.* 84, 852–863. doi: 10.1189/jlb.0308171
- Yu, D.-Y., and Cringle, S. J. (2001). Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease. *Prog. Retin. Eye Res.* 20, 175–208. doi: 10.1016/s1350-9462(00)00027-6
- Yu, S., Cui, K., Wu, P., Wu, B., Lu, X., Huang, R., et al. (2022). Melatonin prevents experimental central serous chorioretinopathy in rats. *J. Pineal Res.* 73:e12802. doi: 10.1111/jpi.12802
- Yun, J. H., Park, S. W., Kim, K. J., Bae, J. S., Lee, E. H., Paek, S. H., et al. (2017). Endothelial STAT3 activation increases vascular leakage through downregulating tight junction proteins: implications for diabetic retinopathy. *J. Cell. Physiol.* 232, 1123–1134. doi: 10.1002/jcp.25575
- Zarkada, G., Howard, J. P., Xiao, X., Park, H., Bizou, M., Leclerc, S., et al. (2021). Specialized endothelial tip cells guide neuroretina vascularization and blood-retina-barrier formation. *Dev. Cell* 56, 2237–2251.e6. doi: 10.1016/j.devcel.2021.06.021
- Zeiner, J., Loukovaara, S., Losenkova, K., Zuccarini, M., Korhonen, A. M., Lehti, K., et al. (2019). Soluble and membrane-bound adenylylase kinase and nucleotidases augment ATP-mediated inflammation in diabetic retinopathy eyes with vitreous hemorrhage. *J. Mol. Med. (Berl)* 97, 341–354. doi: 10.1007/s00109-018-01734-0
- Zeng, Y., Zhang, X., Mi, L., Gan, Y., Su, Y., Li, M., et al. (2022). Characterization of macrophage-like cells in retinal vein occlusion using En face optical coherence tomography. *Front. Immunol.* 13:855466. doi: 10.3389/fimmu.2022.855466
- Zhang, C., Lam, T. T., and Tso, M. O. (2005). Heterogeneous populations of microglia/macrophages in the retina and their activation after retinal ischemia and reperfusion injury. *Exp. Eye Res.* 81, 700–709. doi: 10.1016/j.exer.2005.04.008
- Zhang, T., Ouyang, H., Mei, X., Lu, B., Yu, Z., Chen, K., et al. (2019). Erianin alleviates diabetic retinopathy by reducing retinal inflammation initiated by microglial cells via inhibiting hyperglycemia-mediated ERK1/2-NF-kappaB signaling pathway. *FASEB J.* 33, 11776–11790. doi: 10.1096/fj.201802614RRR
- Zhang, F., Wang, H., Wang, X., Jiang, G., Liu, H., Zhang, G., et al. (2016). TGF-beta induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. *Oncotarget* 7, 52294–52306. doi: 10.18632/oncotarget.10561
- Zhang, Y., Zhao, L., Wang, X., Ma, W., Lazere, A., Qian, H. H., et al. (2018). Repopulating retinal microglia restore endogenous organization and function under CX3CL1-CX3CR1 regulation. *Sci. Adv.* 4:eaap8492. doi: 10.1126/sciadv.aap8492
- Zhao, M., Celerier, I., Bousquet, E., Jeanny, J. C., Jonet, L., Savoldelli, M., et al. (2012). Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. *J. Clin. Invest.* 122, 2672–2679. doi: 10.1172/JCI61427
- Zhao, K., Jiang, Y., Zhang, J., Shi, J., Zheng, P., Yang, C., et al. (2022). Celastrol inhibits pathologic neovascularization in oxygen-induced retinopathy by targeting the miR-17-5p/HIF-1alpha/VEGF pathway. *Cell Cycle* 21, 2091–2108. doi: 10.1080/15384101.2022.2087277
- Zhao, M., Rodriguez-Villagra, E., Kowalczyk, L., Le Normand, M., Berdugo, M., Levy-Boukris, R., et al. (2017). Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. *J. Control. Release* 266, 187–197. doi: 10.1016/j.jconrel.2017.09.029
- Zhao, L., Zabel, M. K., Wang, X., Ma, W., Shah, P., Fariss, R. N., et al. (2015). Microglial phagocytosis of living photoreceptors contributes to inherited retinal degeneration. *EMBO Mol. Med.* 7, 1179–1197. doi: 10.15252/emmm.201505298
- Zhou, T., Huang, Z., Zhu, X., Sun, X., Liu, Y., Cheng, B., et al. (2018). Alpha-1 antitrypsin attenuates M1 microglia-mediated Neuroinflammation in retinal degeneration. *Front. Immunol.* 9:1202. doi: 10.3389/fimmu.2018.01202
- Zhou, L., Xu, Z., Oh, Y., Gamuyao, R., Lee, G., Xie, Y., et al. (2021). Myeloid cell modulation by a GLP-1 receptor agonist regulates retinal angiogenesis in ischemic retinopathy. *JCI Insight* 6. doi: 10.1172/jci.insight.93382
- Zhou, J., Yang, J., Dai, M., Lin, D., Zhang, R., Liu, H., et al. (2020). A combination of inhibiting microglia activity and remodeling gut microenvironment suppresses the development and progression of experimental autoimmune uveitis. *Biochem. Pharmacol.* 180:114108. doi: 10.1016/j.bcp.2020.114108
- Zoller, T., Schneider, A., Kleimeyer, C., Masuda, T., Potru, P. S., Pfeifer, D., et al. (2018). Silencing of TGFbeta signalling in microglia results in impaired homeostasis. *Nat. Commun.* 9:4011. doi: 10.1038/s41467-018-06224-y
- Zoya Tahergorabil, M. K. (2012). A review on angiogenesis and its assays. *Iran. J. Basic Med. Sci.* 15, 1110–1126.